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“In general, the benefits of proven medical therapies are available only to patients who 
actually use them.” 
Richard Kravitz 
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1. INTRODUCTION 
1.1. Adherence 
Chronic diseases, defined as diseases with a long, indefinite duration and little prospect 
of immediate change, are considered to be a major future health care challenge 1. 
Having a chronic disease often implies life-long therapy in order to prevent or delay 
progression of the disease. Obviously, the effectiveness of therapies depends on 
patients’ level of adherence. Adherence to the therapy is therefore a cornerstone 
requirement of successful chronic illness management 2. 
Adherence (also called compliance or concordance) can be defined as « the extent to 
which a person’s behaviour – taking medication, following a diet, and/or executing 
lifestyle changes, corresponds with agreed recommendations from a health care 
provider » 3. It « is a behavioral process, strongly influenced by the environment in 
which the patient lives, including the health care practices and systems. Adherence 
assumes that a patient has the knowledge, motivation, skills and resources required to 
follow the recommendations of a health care professional.» 4 
1.2. Adherence in transplantation 
Solid organ transplant recipients are chronically ill patients, because the transplantation 
did not fully eliminate the need for medical treatment. Recipients have to adhere to a 
life long medication regimen that prevents the immune system from rejecting the 
transplant and manages emerging co-morbidities 5 6 7. Reduceing the risk for rejection 
requires a high degree of adherence to the prescribed immunosuppressive. However, 
despite the dangers related to imperfect adherence, previous research has shown that 
a substantial proportion of solid organ recipients fail to take their immunosuppressives 
as prescribed. An estimated 20 to 25% of the adult heart, liver and renal transplant 
patients are non-adherent to their immunosuppressive therapy 7. Non-adherence is 
expected to cause 20% to 90% of late acute rejections and 16% to 23% of graft 
losses in solid organ transplant recipients 7. Furthermore, the non-adherence problem 
is expected to be one of the causes for yet unexplained but observed stagnation in 
long-term kidney graft survival 8. Economic consequences are a higher cost per quality 
adjusted life year 9. 
Improving outcomes in solid organ transplantation is considered to be one of the main 
goals in transplant research and clinical management of transplant patients for the 
upcoming years 10. A possible strategy to reach that goal is to enhance adherence in 
patients. A prerequisite to enhancing adherence is that patients at risk for non-
adherence can be identified, which implies that studies are needed that unveil risk 
factors of adherence behavior. Risk factors for non-adherence are manifold. In 2003, 
the WHO published a taxonomy of risk factors of non-adherence (see figure) 3. Risk 
factors in this model can be socio-economic, therapy-, patient-, condition-, and health 
care system- or health care worker-related. Adherence research has primarily focused 
on socio-economic, patient-, condition- and treatment-related factors. The WHO 
framework aims at directing attention to risk factors from all adherence-determining 
dimensions including health care related factors 3. As the main aim of this research 
program is to investigate risk factors for non-adherence to immunosuppressive drugs 
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in kidney transplant patients, the WHO model will be used as a guiding framework in 
this dissertation. 
 
Fig. 3. WHO framework: the five dimensions of non-adherence 
1.3. Measurement of non-adherence 
A prerequisite for quantitatively investigating adherence behavior is that adherence can 
be assessed in a valid way. Unbiased methods are needed that capture non-adherence 
in its sub-clinical stage (i.e. before recurrent rejections or graft loss suggest non-
adherent behavior). Several measurement methods exist, recently concisely discussed 
in a review article published in the New England Journal of Medicine 11. Measurement 
methods relevant for solid organ transplantation can be divided into two groups: direct 
or indirect measures. 
Direct measures, i.e. observation of medication intake and biological assay of drug 
levels or drug metabolites in the blood or urine, permit examining actual drug ingestion 
11 12. Observation is a very labor-intensive method, not feasible in non-clinical settings, 
and thus not very common in transplantation research. Blood assay on the other hand 
is used more frequently in routine clinical practice to assess levels of 
immunosuppressive. A disadvantage of assay is that it does not capture intake 
dynamics and that “white coat-compliance”, referring to patients taking their 
medication before a clinic visit in which a blood sample will be taken, may bias the 
results. 
Indirect measures do not prove actual intake of the medication; rather, they estimate 
how much patients could have ingested based on information coming from patient self-
reports or diaries, collateral reports from family members or clinicians, rates of 
prescription refills, pill counts, or electronic monitoring (EM). The advantage of most of 
these indirect methods (except for EM) is that they are relatively easy to use, often at 
the expense of a lower sensitivity or validity 11 12. This, however, does not apply to EM 
13 14. EM is a technologically advanced method, which relies on microprocessor 
equipped pill packages or bottles that register their opening times to assess adherence 
behavior. EM is today’s most sensitive adherence measure 15. It measures adherence 
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with great resolution, and unveils not only the taking dimension but also the temporal 
dynamics of medication taking. For research purposes, EM became the assessment 
method of choice over the last years. This does not mean, however, that EM is the 
perfect method. Despite its nice diagnostic properties, many researchers are reluctant 
to declare EM the gold standard method in adherence research, as EM’s alleged 
superiority has not really been thoroughly substantiated in research yet 11. In an recent 
editorial contribution elaborating on the validity of non-adherence measurement 
methods, DiMatteo, an authority in the area of adherence, therefore included EM 
among the methods that need to be scrutinized in future research: “To obtain a firmer 
grip on the best measurement methodologies, it will be necessary to compile and 
assess the value, appropriateness, reliability, and validity of a wide range of possible 
measurement strategies. […] Our findings about the prevalence, correlates, and 
consequences of nonadherence will always be tied to the methods we use, so we must 
understand them better.” “Research is needed that carefully examines measurement 
and methodology issues, including numerous adherence measurement strategies such 
as […] electronic monitoring.” 16 
Because the main study of this dissertation will use EM as a measurement method for 
non-adherence, we will comply with DiMatteo’s call by including a section on validity of 
EM measurement. 
1.4. Outline of the research program 
This dissertation consists of four chapters, of which the first two prepare the reader for 
the two main risk factor studies described in the last two chapters. 
The literature review presented in chapter one summarizes the evidence on the 
prevalence, determinants, clinical and economic consequences of non-adherence with 
immunosuppressive drugs in renal transplant patients. A literature search, which 
yielded 38 articles was used to calculate 1) weighted mean prevalences of non-
adherence and 2) weighted mean prevalences of rejection episodes or graft losses that 
can be attributed to non-adherence. In addition, economic consequences of non-
adherence will be reviewed. Investigated risk factors of non-adherence will be 
summarized using the WHO framework, and suggestions are made for further 
research. 
Chapter two summarizes existing knowledge about the validity of electronic medication 
monitoring. A framework systematizing sources of bias in EM assessment is presented. 
The framework discerns internal and external assumptions underlying unbiased EM 
measurement. Internal validity assumptions presuppose (1) correct functioning of the 
EM equipment, (2) correspondance between EM-bottle openings and actual intake of 
the prescribed doses, and (3) absense of influence of EM on a patient’s normal 
adherence behavior. External validity refers to EM biasing the representativeness of the 
sample. The four validity assumptions were tested using data from the Supporting 
Medication Adherence in Renal Transplantation (SMART) study, which included 250 
adult renal transplant patients whose adherence to immunosuppressive drugs was 
measured over a 3-month period by EM 17. 
Chapter three is a prospective study assessing prevalence and risk factors of non-
adherence, using SMART study data. Adherence was measured by EM in 250 adult 
renal transplant patients. A number of selected socio-economic, therapy-, patient-, 
condition- and health care team-related risk factors were explored for association to 
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non-adherence. Longitudinal analysis techniques were used that allowed including 
time-varying covariables and fitting multivariable models. 
Chapter four addresses an underinvestigated area in risk factor research, i.e. health 
care team-related risk factors. More specifically, the study explored the relationship 
between the health care system and prevalence of self-reported non-adherence with 
immunosuppressives by focusing on variations in non-adherence prevalences between 
European and North American renal transplant patients. The study used methods of 
meta-analysis on individual patient data, combining three independent cross-sectional 
studies of comparable methodology that included patients from the US (N=1563) 18, 
the Netherlands (N=85), Belgium (N=187) 19 and Switzerland (n=342) 17. 
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2.1. Introduction 
Despite the introduction of powerful immunosuppressive agents and a continuous 
decrease of acute rejection episodes over the last decades, recent data show that long-
term renal allograft survival only marginally improved. Indeed, graft survival in first 
transplants only increased by a mere 5 months between 1988 and 1995 1. In addition, 
overall graft survival remained at the same level between 1995 and 2000 2. This 
suggests that current therapeutic interventions do not efficiently prevent the 
development of chronic allograft nephropathy, which accounts for 40-50% of late 
allograft losses 3. Chronic allograft nephropathy is the consequence of any 
immunological (i.e. clinical or subclinical allograft rejection) or non-immunological 
injury (e.g. calcineurin-inhibitor nephrotoxicity, hypertension, infections) to the renal 
allograft. The immunosuppressive therapy, which should be adapted to the needs of 
every patient, balances the risks for rejection and over-immunosuppression. 
Non-adherence with the immunosuppressive therapy is a behavioral factor that also 
needs to be scrutinized. Although non-adherence is regarded as one of the major 
causes of late renal allograft failure 4, due to variability in exposure of the kidney to 
immunosuppressives 5-9, or simply by a discontinuation of drug intake 10 11, it only 
receives limited attention when discussing the etiology of graft loss in the literature 3 12 
13. Understanding the behavioral dimension of transplant patients’ management in view 
of prevalence, consequences and determinants of non-adherence with 
immunosuppressive drugs is a prerequisite for targeting non-adherence as a potential 
modifiable risk factor for poor outcome. The goal of this literature review is therefore 
to summarize the existing evidence on non-adherence with the immunosuppressive 
therapy in adult renal transplant recipients, more specifically to summarize and discuss: 
1) measurement methods for assessing non-adherence, 2) prevalence, 3) clinical as 
well as economical consequences, and 4) determinants of non-adherence. 
2.2. The behavioral dimension of kidney transplantation 
The therapeutic regimen of renal transplant recipients consists of medication taking, 
infection prevention, smoking cessation, clinic visit attendance, and of following 
guidelines concerning alcohol intake, diet and exercise. “Adherence”, a key component 
of the behavioral dimension of transplant patient’s therapeutic regimen, also called 
“compliance” or “concordance”, refers to “the extent to which a person’s behaviour – 
taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with the agreed recommendations from a health care provider” 14. 
Adherence with the immunosuppressive regimen can be measured by various direct 
and indirect methods. Direct methods refer to observation and assay of medications or 
medication by-products. Indirect methods include self-report, pill count, prescription 
refills, collateral report, clinical outcome, and electronic monitoring (EM). EM refers to a 
pill bottle that contains a microprocessor fitted cap to save the date and time of each 
opening 15. Despite the fact that the registration of a pill box opening does not prove 
ingestion, EM shows superior sensitivity compared to other methods, as shown in 
cross-validation studies 16. Moreover, EM allows assessing non-adherence as a 
continuous variable in a multidimensional manner (i.e. the taking and timing dimension 
of medication taking). Self-report often results in underreporting of non-adherence 16 
17. Assay, despite being a direct method, only allows determining medication intake 
over a limited time period, depending on the half-life of the drug. Also, “white coat 
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adherence”, referring to patient’s correct intake in the light of a pending clinic visit, 
might further distort interpretation of therapeutic blood levels 18. 
We screened abstracts from the database of Medline, Cinahl and Psycinfo (1988-2004) 
for English, Dutch, French or German studies focusing on prevalence, determinants 
and consequences of non-adherence with immunosuppressive drugs in non-pediatric 
renal transplant patients, using the following keywords: (kidney or renal) and 
transplan* and (adheren* or complian* or nonadheren* or noncomplian*). The 
Medline search yielded 569 abstracts, of which 34 focused on prevalence and/or 
consequences and/or determinants of nonadherence. Exploration of the reference lists 
yielded another four articles. The Cinahl and Psycinfo databases did not provide extra 
studies. 
2.3. Prevalence of non-adherence 
Seventeen studies reported on prevalence of non-adherence with immunosuppressive 
drugs in kidney transplantation (Table 1). The prevalences of non-adherence varied 
widely, ranging from 2% to 67%, depending on the used operational definitions, case 
finding and measurement methods. A weighted mean prevalence, calculated over all 
studies that measured non-adherence by self-report, was 27.7% (n=10). One study, 
the only one measuring non-adherence by medical chart review, found a very low non-
adherence prevalence of 2%. Given the higher prevalences in other studies, chart 
review seems to lack sensitivity in capturing non-adherence 19. The fact that non-
adherence is not assessed as a standard clinical parameter in most transplant 
programs may explain this low percentage. 
Two studies provided electronically monitored period prevalence estimates of non-
adherence, using adherence parameters that express the taking and timing dimension 
of non-adherence 20 21. Although no clinical meaningful cut-off to classify patients in 
adherers and non-adherers in the renal transplant population has been developed so 
far, these studies considered patients as being non-adherent if they had taken less 
than 90% of the prescribed doses, resulting in a 26% 21 and 20% 20 non-adherence 
prevalence. Future studies should define cut-off values, indicating which level of non-
adherence results in late acute rejection or graft loss. Research in the heart transplant 
population already showed that minor deviations from dosing schedule were associated 
with late acute rejections (> 1 year after transplantation) 22. 
This evidence about the prevalence of non-adherence with immunosuppressive 
regimen in renal transplantation indicates the widespread nature of the problem. To 
better understand the relevance of non-adherence, its relation with poor outcomes 
(e.g. acute rejection episodes and allograft loss) needs to be explored. 
2.4. Consequences of non-adherence 
Consequences of non-adherence can be categorized in clinical and economic 
consequences. Clinical consequences can be examined by assessing the effect of 
subclinical non-adherence on clinical outcomes, or by retrospectively looking for causes 
of acute rejections or graft losses. 
  
Table 1: Studies estimating the prevalence of non-adherence with immunosuppressive medication in renal transplant recipients 
Study Description of the Sample N Non-adherence conceptualization and measurement Prevalence of 
non-adherence 
Butler et al. 2004 21 RTX recipients > 18 years old, ≥ 6 months post-
transplant; on Pred; UK 
60 Electronic monitoring during 6 weeks 
1) Missed at least 20% of the prescribed doses 
2) Missed at least 10% of the prescribed doses 
 
1) 12% 
2) 26% 
Ghods et al. 2003 24 RTX recipients > 1 year post-transplant; 95% on 
CyA (+ sometimes MMF), 5% are on AZA/Pred; 
Iran 
267 Self-report: missing ≥ 3 doses per month 21=7.9% 
Vasquez et al. 2003 25 Adult RTX recipients with functioning graft; on CyA 
and MMF; US 
95 1) Self-report: missed dose since the last visit or in the week 
prior to receipt of the study survey 
2) Assay: 3 successive CyA < 50 ng/ ml or FK < 5ng/ml in the 
absence of CNI metabolism affecting drugs, or absorption 
problems 
1) 44=46.3% 
 
2) 16=16.8% 
Total: 52=55% 
Nevins et al. 2001 20 Newly transplanted RTX recipients, transplanted 
between 1993 and 1995; on AZA; US 
134 Electronic monitoring during 6 months after discharge 
 1) Average percentage of correctly dosed days 
 2) Percentage taking less than 90% of the prescribed 
doses 
 
1) 88.1% 
2) 20% 
Butkus et al. 2001 26 RTX recipients, RTX between 1992 and 1997; US 128 Not stated 11=9% 
Chisholm et al. 2000 66RTX recipients > 18 years old, 8-12 months post-
transplant, receiving immunosuppressives at no 
cost, RTX between 1997 and 1998; patients on 
CNI; US 
18 Refill record count: non-adherence if < 80% of prescribed 
medication refilled 
12=66.7% 
Teixeira de Barros et 
al. 2000 56 
RTX recipients transplanted between 1995-1997; 
Portugal 
113 Six 4-monthly self-report evaluations in 2 years period: 
admission ≥ 2 evaluations to having skipped a dose or to 
having deviated >2.5 hours from the prescribed dosage 
schedule 
18=16.8% 
Raiz et al. 1999 57 RTX recipients > 18 years old, first transplants, 
with functioning graft > 12 months post-
transplant; transplanted between 1985 and 1994; 
US 
357 Self-report: not taking medications like instructed less than 
once a week or more 
32.5% 
Greenstein & Siegal 
1998 58 
RTX recipients >18 years old, with functioning 
graft; on CNI; 56 centers in the US 
1402 Self-report: having missed ≥ 1 doses of immunosuppressive 
medication in the previous 4 weeks 
314=22.4% 
  
Study Description of the Sample N Non-adherence conceptualization and measurement Prevalence of 
non-adherence 
Siegal & Greenstein 
1997 59 
RTX recipients > 18 years old, with functioning 
graft, on CyA, 5 centers, US 
519 Self-report: having missed ≥ 1 doses of immunosuppressive 
medication in the previous 4 weeks 
69=18% 
De Geest et al. 1995 
31 
RTX recipients > 18 years old, at least 1 year 
post-transplant, Dutch speaking; on CyA; Belgium
148 Self-report 22.3% 
Frazier et al. 1994 61 RTX recipients, transplanted between 1987 & 
1990; US 
241 Self-report: 11 items scale measuring medication non-
adherence, defined as missing a dose at least “sometimes”  
45%  
Sketris et al. 1994 60 RTX recipients on CyA; sampled from 2 centers in 
Canada 
361 Self-report: admission of at least one of the criteria: 
- taking a smaller or larger dose > once per week 
- taking > 2 hours before/after the indicated time > once per 
week 
- not taking a dose > once per month 
65%  
Kalil et al. 1992 19 RTX recipients > 1st year post-transplant, 
transplanted between 1976-1982; on AZA/Pred; 
US 
202 Medication non-adherence reported in the medical chart 4=2% 
Butkus et al. 1992 34 1st cadaveric RTX recipients, transplanted between 
1985-1991; on CyA; US 
100 Composite measure: ≥ 3 consecutive missed clinic visits, 
immeasurable blood CyA on 2 consecutive visits in the absence 
of another explanation, or leaving hospital against advice 
10=10% 
Rovelli et al. 1989 51 RTX recipients > 3 months post-transplant, 
experiencing no rejection < 3 m; transplanted 
between 1971-1984; US 
260 Medical record report of: 
1. Appointment non-adherence 
2. Medication non-adherence: admission of patients/family 
47=18% 
 Same inclusion criteria, but transplanted after 
1984. Patients also received adherence enhancing 
education before transplantation 
196 Medical record report of: 
1. Appointment non-adherence 
2. Medication non-adherence: admission of patients/family 
30=15% 
 
Didlake et al. 1988 49 RTX recipients, RTX between 1982-1986; on CyA; 
US 
185 Self-report: omitting ≥ 1 dose per month 36=19.5% 
 
Abbreviations: AZA = azathioprine; CyA = cyclosporine; CNI = calcineurin inhibitor; FK = tacrolimus; MMF = mycophenolate mofetil; Pred 
= prednison; RTX = renal transplant
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2.4.1. Clinical consequences 
Fifteen studies examined the association between subclinical non-adherence and 
clinical outcome 19 20 23-34. Three prospective cohort studies 20 23 32, one of which 
measured non-adherence electronically 20, demonstrated that non-adherence is a risk 
factor for late acute rejection and late graft loss (Table 2). These studies only took into 
account acute rejection and graft loss events if occurring after 3 months 20 32 or 1 year 
post-transplant 23. Ten retrospective cohort studies, admittedly a weaker design, 
further confirmed the relationship between (late) acute rejection 24 25 29-31, graft 
loss/graft survival 19 26 28-30 34, patient survival 31, and graft dysfunction (defined as 
serum creatinine being ≥ 5mg/dl) 24. Two retrospective studies focusing on the 
relationship between non-adherence and chronic allograft nephropathy failed to find a 
direct link 31 35. However, it is worth noting that acute allograft rejection is the major 
risk factor for developing chronic allograft nephropathy 36 37. Given that non-adherence 
substantially contributes to late acute rejection 37, an indirect link between non-
adherence and chronic allograft nephropathy can be suggested. 
Eighteen studies estimated the contribution of non-adherence in the etiology of graft 
losses and acute rejections, attributing up to 64% of the graft failures 27 28 34 38-49 and 
80% of the late acute rejections to non-adherence 50 51, depending on case finding and 
measurement methods. Averaging these percentages by a weighted mean over the 
publications that met the methodological requirement of having formally assessed non-
adherence, resulted in an estimated contribution of non-adherence to graft losses of 
16.3% for graft losses (n=8), and to late acute rejections of 19.9% (n=3) (Table 3). 
These percentages probably underestimate the contribution of non-adherence in poor 
clinical outcome, as assessment of non-adherence in clinical practice rarely occurs in a 
routine and standardized way. Illustrative in this regard are the results of a study in a 
single heart transplant center that initially reported to the “United Network for Organ 
Sharing” database that non-adherence was the etiological factor in 2% of graft losses. 
Detailed reevaluation revealed that actually 13% of the graft losses were related to 
non-adherence 52. Given the contribution of non-adherence to the development of 
acute rejection and graft loss, it should be worthwhile to integrate a routine and 
standardized measurement of non-adherence in transplant registries or large outcome 
studies. Currently, categories such as “acute rejection” or “chronic allograft 
nephropathy” mask non-adherence, resulting in underreporting of non-adherence as 
an important contributor to poor outcome 28. 
Also, since most studies assessing the relationship between non-adherence and 
outcome include patients on older immunosuppressants (e.g. azathioprine, 
cyclosporine), priority should be given in future research to assess if the found 
associations also apply for newer immunosuppressive regimens (e.g. tacrolimus, 
sirolimus, mycophenolate). 
  
Table 2: Studies testing the clinical consequences of non-adherence with immunosuppressive medication in renal transplant recipients 
Study Description of the sample N Design Non-adherence concept-
ualization and measurement 
Outcome Analysis Results: consequences of 
non-adherence 
Vlaminck 
et al. 
2004 23 
RTX recipients that were > 18 
years, at least 1 year post- 
transplant, Dutch speaking; 
Belgium; on CyA 
146 Prospective 
cohort study 
Self-reported NA measured at 
inclusion, defined as having 
regular dose omissions in the 
past 1 year 
Late acute rejection 
(biopsy proven) 
Cox 
regression 
controlling 
for other 
influences 
Rejection-free time is shorter 
in non-adherent than in 
adherent recipients (p=0.04) 
     Graft function Mixed 
model 
A significantly higher increase 
in serum creatinine in 
adherent patients after RTX 
(p<.001) 
Ghods et 
al. 2003 
24 
RTX recipients > 1 year post-
transplant (data gathering in 
2001-2002); 95% on CyA, 5% 
on AZA/Pred; Iran 
267 Retrospective 
cohort study 
Self-report: missing ≥ 3 doses per 
month. If nonconsecutive: minor 
NA, if consecutive: major NA 
Late acute rejection Not 
mentioned 
Higher number of acute 
rejections in non-adherers 
(p<.001) 
     Graft dysfunction 
(serum creatinine ≥ 
5mg/dl) 
Not 
mentioned 
More graft dysfunction in 
non-adherers (p<.01) 
Vasquez 
et al. 
2003 25 
Adult RTX recipients with 
functioning graft; on CyA & 
MMF; US 
95 Retrospective 
cohort study 
1. Self-report: a missed a dose 
since the last visit or in the week 
prior to receipt of the study 
survey 
2. Assay: 3 successive CyA blood 
levels < 50 ng/ ml or FK < 
5ng/ml in absence of CNI 
metabolism affecting drugs, or 
absorption problems 
Acute rejection Logistic 
regression 
More chance on experiencing 
acute rejection if non-
adherent (p<.001) 
 
Butkus et 
al. 2001 
26 
RTX recipients; transplanted 
between 1992 and 1997, US 
128 Retrospective 
cohort study 
No operationalization given Graft survival Kaplan 
Meier 
Shorter survival in grafts of 
non-adherent recipients 
(p<.0001) 
Nevins et 
al. 2001 
RTX recipients, > 90 days 
after transplantation 
134 Prospective 
cohort study 
Electronic monitoring  Late acute rejection 
(clinical diagnosis or 
Kaplan 
Meier 
Rejection-free survival is 
longer in adherent patients 
  
Study Description of the sample N Design Non-adherence concept-
ualization and measurement 
Outcome Analysis Results: consequences of 
non-adherence 
20 discharge, independent 
medication management; 
1993-1995; on AZA; US 
biopsy proven) 
 
(p=.006) 
     Graft survival (all 
deaths counted as graft 
loss) 
Kaplan 
Meier 
More graft loss in non-
adherent patients (p<.002) 
     Patient survival / Death occurred to 
infrequently to perform tests 
Papajcik 
et al. 
1999 35 
1. RTX with functioning graft ≥
1y post transplant, with biopsy 
confirmed chronic rejection; 
transplanted between 1987-
1994 
2. Matched group without 
chronic rejection 
77 + 
49 
Case-control 
study 
Missing ≥ 1 of the following tasks 
≥ 5 times per year for ≥ 2 
consecutive years: 
1. Having lab tests done 
2. Attending follow-up 
appointments 
3. Taking immunosuppressives 
Chronic rejection Chi²-test No adherence-difference 
found between the chronic 
rejection (12% AH) and the 
non-chronic rejection group 
(23% AH) (p=.11) 
 
     Late graft survival Kaplan 
Meier 
No significant difference 
found (p=.31) 
Isaacs et 
al. 1999 
27 
RTX living related donor 
transplants between 1988-
1994; multi-center study on a 
registry of all patients in the 
US 
10865 Retrospective 
cohort study 
No operationalization given Graft survival Cox-
regression 
No significant relationship 
found  
Gaston 
et al. 
1999 28 
Kidney & kidney-pancreas 
transplantation with graft loss 
due to chronic rejection 
beyond 6 months transplanted 
between 1992 & 1995, on CyA
1150 Retrospective 
cohort study 
Two of the following criteria: 1) 
admission of non-adherence by 
the patient, documented in 
medical record; 2) Failure to keep 
scheduled appointments; 3) 
Undetectable CyA levels on > 1 
occasion (if no instruction to 
withhold CyA) 
Late graft loss Not 
mentioned 
Graft loss occurred earlier in 
NA patients with chronic 
rejection (p<.05) 
Rudman 
1999 29 
RTX recipients that did not 
loose the graft in the first 2 
374 Retrospective 
cohort study 
1. Non-adherence = 3 missed 
calls in a row, in which the 
Graft loss 
 
Correlation Positive significant 
relationship of NA with graft 
  
Study Description of the sample N Design Non-adherence concept-
ualization and measurement 
Outcome Analysis Results: consequences of 
non-adherence 
months posttransplant; data 
gathering 
patient should transfer the lab 
data results 
loss (no probability 
mentioned) 
 restricted to 12 months; US   2. Collateral report by 4 staff 
members 
Rejection Correlation Positive significant 
relationship of NA with the 
number of rejection episodes 
(no probability mentioned) 
If graft loss occurred, 44% 
were NA pre-transplant vs. 
13% adherent (p <.01) 
Douglas 
et al. 
1996 30 
RTX recipients that were >18 
years at transplantation, 
without rejection due to 
technical failure or rejection 
<3 months, that survived >3 
months; transplanted between 
1986-1988; US 
126 Retrospective 
cohort study 
Non-adherence if documented in 
the pre-transplant evaluation 
chart (appointment non-
adherence, use of illicit drugs, …) 
Late graft loss 
 
 
Chi²-test 
If graft loss occurred: 44% 
were NA post-transplant vs. 
17% adherent (p<.01) 
A mean of 1.43 rejections if 
adherent pre-transplant; and 
1.65 rejections if not 
adherent (not significant) 
     Late rejection (Biopsy 
proven) 
F-test 
 
 
A mean of 1.03 rejections if 
adherent post-transplant, and 
1.93 rejections if not 
adherent (p<.0001) 
De Geest 
et al. 
1995 31 
RTX recipients that were > 18 
years, at least 1 year post-
transplant, Dutch  
148 Retrospective 
cohort study 
Self-report Late acute rejection Mann 
Whitney U 
More rejection in non-
adherers (p=.003) 
 speaking; Belgium; on CyA    Chronic rejection  No significant difference 
(p=.70) 
     5y patient survivival Kaplan 
Meier 
Longer patient survival if 
adherent (p=.03) 
     5y graft survival   No significant difference 
Hilbrands 
et al. 
1995 32 
Adult 1st or 2nd RTX 
recipients > 3m post-RTX, 
cadaveric grafts, no psychiatric 
113 Prospective 
cohort study 
Pill-count: the sum of the 
monthly assessed, but 
dichotomized% of prescribed 
Late acute rejection 
(Biopsy proven in 81%)
Mann-
Whitney U 
More underconsumption of 
medication in patients 
experiencing rejection 
  
Study Description of the sample N Design Non-adherence concept-
ualization and measurement 
Outcome Analysis Results: consequences of 
non-adherence 
disease, no alcohol abuse, 
knowledge of Dutch; Study 
was part of a trial comparing 
CyA with AZA+Pred 
medications taken  (p<.01) 
Pirsch et 
al. 1996 
33 
RTX recipients with 1st 
cadaveric grafts, transplanted 
between 1986 & 1992; on 
AZA/Pred of CyA; multi-center 
UNOS data base; US 
589 Retrospective 
cohort study 
No operationalization given Rejection (clinical signs 
& biopsy) 
Cox 
regression 
Not significant 
Butkus et 
al. 1992 
34 
1st cadaveric RTX between 
1985-1991; on CyA; US 
100 Retrospective 
cohort study 
≥ 3 consecutive missed clinic 
visits, immeasurable blood CyA 
on 2 consecutive visits in the 
absence of another explanation, 
leaving hospital against advice 
Graft survival Not 
mentioned 
Degree of adherence 
significantly related to graft 
survival (no probability 
mentioned) 
Kalil et 
al. 1992 
19 
RTX surviving the 1st year, 
transplanted between 1976-
1982; on AZA/Pred; US 
202 Retrospective 
cohort study 
- NA reported in the medical 
chart 
- The dichotomized percentage of 
prescribed creatinine-level  
Late graft survival Kaplan 
Meier 
Better graft survival in 
adherent patients (p<.01) 
    measurements the patient 
transferred to the center.  
Patient survival Kaplan 
Meier 
No significant difference  
Abbreviations: AZA = azathioprine; CyA = cyclosporine; CNI = calcineurin inhibitor; FK = tacrolimus; MMF = mycophenolate mofetil; NA 
= non-adherent Pred = prednison; RTX = renal transplant 
  
Table 3: Studies estimating the contribution of non-adherence with immunosuppressive medication on late acute rejection or graft loss 
Author Description of the sample (all consist 
of patients experiencing graft loss) 
N Non-adherence conceptualization & 
measurement 
Outcome Estimated % poor 
outcomes due to 
non-adherence 
Michelon 
2002 et al. 38 
RTX recipients; RTX between 1977-1999; 
on AZA/Pred, AZA/Pred/CyA, 
MMF/CyA/Pred, Fk/AZA/Pred; Brazil 
1027 Patient admitted that non-adherence was the cause 
of the graft dysfunction 
Graft loss 47/448 = 10.5% 
Matas 2002 et 
al. 39 
RTX recipients; RTX in the 1990s, on CyA, 
AZA/MMF & Pred; US 
534 Non-adherence was mentioned in the medical file Graft loss 11.7% 
Michelon 1999 
et al. 41 
RTX recipients; RTX between 1977 and 
1991; on AZA/ Pred&AZA/ Pred/ CyA; Brazil
1027 Patient or relative admitted that non-adherence was 
the cause of the graft loss when coming back on 
dialysis 
Graft loss 48/385 = 12.5%  
Gaston 1999 et 
al. 28 
Kidney & Kidney-pancreas transplantation 
with graft loss due to chronic rejection 
beyond 6 months; transplanted between 
1992 & 1995; on CyA; US 
1005 Two of the following criteria: 
- admission of non-adherence by the patient, 
documented in the medical record 
- failure to keep scheduled appointments in 
outpatient transplant clinic 
- undetectable CyA levels on > 1 occasion in the 
absence of physician instruction to withhold CyA 
Graft loss 64/184 = 34.8% 
Garcia 1997 et 
al. 42  
RTX recipients, > 6 months post-transplant, 
RTX between 1977-1995. Patients received 
education about importance of adherence 
after 1991; Brazil 
562 When coming back on dialysis, the patient or a 1st 
degree relative admitted that regular medication 
intake was not rule  
Graft loss 24/139= 17.2% 
Reinke et al 
1994 50 
RTX recipients with impaired graft function 
≥ 2 year post-transplant; on CyA/pred, 
AZA/Pred, CyA/AZA, or triple therapy; 
Germany 
432 Assay of CyA & sometimes AZA Late acute 
rejection 
4/157=2.5% 
Kiley 1993 et 
al. 46 
RTX recipients, RTX between 1985-1987; 
on CyA; US 
105 Repeated CyA assays < 30 ng/ml in the absence of 
factors likely to affect the CyA levels 
Graft loss 9/14 = 64.3% 
Butkus 1992 et 
al. 34 
First cadaveric kidney transplant recipients; 
RTX between 1985-1991; on CyA; US 
100 ≥ 3 consecutive missed clinic visits; immeasurable 
blood CyA on 2 consecutive visits (in the absence of 
another explanation); or leaving hospital against 
medical advice 
Graft loss 10/46 = 21.7% 
  
Author Description of the sample (all consist 
of patients experiencing graft loss) 
N Non-adherence conceptualization & 
measurement 
Outcome Estimated % poor 
outcomes due to 
non-adherence 
Hong 1992 et 
al. 47 
RTX recipients > 1y post-transplant; 
RTX between 1983-1989; on CyA & 
tapering Pred; US 
654 Self-admission or non-adherence, failure to attend 2 
consecutive visits, or CyA level below 25 ng/ml that 
normalizes after CyA administration in the hospital 
Graft loss 15/83 = 18.1% 
Didlake 1988 et 
al. 49 
RTX recipients; RTX between 1982-1986; 
on CyA; US 
531 Initial CyA blood levels < 25ng/ml and rose upon in-
hospital administration of the prescribed dose 
Graft loss 15/126 = 11.9% 
Rovelli et al. 
1989 51 
RTX recipients, > 3 months post-transplant, 
experiencing no rejection < 3 m; 
transplanted between 1971-1984; US 
260 Medical record report of: 
1. Appointment non-adherence 
2. Medication non-adherence: admission of 
patients/family 
Late acute 
rejection 
36/74=48.6% 
 Same criteria, but transplanted after 1984. 
Patients also received adherence enhancing 
education before transplantation; US 
196 Medical record report of: 
1. Appointment non-adherence 
2. Medication non-adherence: admission of 
patients/family 
Late acute 
rejection 
8/10=80.0% 
 
Abbreviations: AZA = azathioprine; CyA = cyclosporine; CNI = calcineurin inhibitor; FK = tacrolimus; MMF = mycophenolate mofetil; Pred 
= prednison; RTX = renal transplant
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2.4.2. Economic consequences 
Economic consequences of non-adherence have rarely been examined according to the 
best available standards for economic evaluation 53. One study estimated that the 
additional hospital cost associated with non-adherence amounts to 900$ per patient 
per year 54. This figure, however, incompletely reflects the actual costs, as non-
adherence not only impacts upon hospital costs but also on other cost categories, such 
as ambulatory care costs, nursing home care costs, productivity losses and patients' 
and their family's out-of-pocket expenses. 
To grasp the full economic impact of non-adherence, it is necessary to consider both 
costs and outcomes in a cost-effectiveness or cost-utility analysis. Non-adherence after 
renal transplantation may have two opposite consequences that make it difficult to 
determine a priori what its consequences will be on the cost-effectiveness of renal 
transplantation. On the cost side, non-adherence may entail additional costs due to the 
occurrence and consequent treatment of late acute rejection or graft loss. However, 
adherent patients may experience more negative side effects related to 
immunosuppressive medication intake that also require additional treatment. The 
balance between the costs of adherence and non-adherence then becomes blurred. On 
the outcome side, non-adherence – if deliberate – may increase patients' life 
satisfaction, for instance through the experience of less side effects and more flexibility 
in medication intake. This quality of life improvement may (partly) offset the quality of 
life loss associated with increased morbidity. Again, the net effect is unclear. 
Only one cost-utility study has assessed the economic consequences of non-adherence 
in a renal transplant population. Cleemput et al. 55 found that because non-adherent 
patients have a lower life expectancy, their lifetime treatment costs are lower (a dead 
patient is the cheapest patient). Lifetime costs for adherent patients were estimated to 
be 38 180 € higher than for non-adherent patients. As for the outcomes, non-adherent 
patients had a worse outcome than adherent patients in terms of both life expectancy 
and quality adjusted life expectancy. Both outcomes were summarised in a single 
outcome measure: Quality Adjusted Life Years (QALYs). Adherent patients gained 
approximately 1.108 QALYs more after RTX than non-adherent patients 55. This implies 
that the incremental cost-effectiveness of adherence relative to non-adherence after 
RTX was 35 021 €/QALY. The incremental cost-effectiveness ratio will ultimately 
determine the relative cost-effectiveness of adherence-enhancing interventions 55. For 
an adherence enhancing intervention to be cost-effective, it is important that its cost-
effectiveness ratio, added to the cost-effectiveness ratio of adherence relative to non-
adherence does not exceed the societal willingness to pay for a QALY. 
2.5. Determinants of non-adherence 
Non-adherence can be considered as a phenomenon that emerges from the interplay 
of numerous influential factors, categorized into five groups: 1) socio-economic factors, 
2) patient related factors, 3) condition or disease related factors, 4) therapy or 
treatment related factors, and 5) health care system and health care team related 
factors 14. Determinants from all categories except for health care system and health 
care team related factors have to a certain extent been studied in kidney transplant 
patients 19 21 23-25 27 29-31 34 35 51 56-61. The following section discusses the findings of these 
studies. Table 4 summarizes the evidence from all performed prospective cohort 
studies 21 23 56. 
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2.5.1. Socio-economic factors 
Socio-economic variables have been explored most often. Almost every study included 
the variable age, showing that non-adherence is nearly consistently associated with 
being younger 21 24 30 35 51 57-61. Studies failing to confirm this finding mostly lack a 
significant subsample of adolescents 23 25 31 51. One could therefore hypothesize that the 
found linear association between non-adherence and younger age mainly depends on 
the presence of (non-adherent) adolescents at the lower end of the age spectrum. 
Without adolescents, non-adherence might remain quite stable over the life course, at 
least before major cognitive, sensory and functional impairment appear when 
becoming older. Facing the aging transplant population, increasing attention needs to 
be given to potential age related risk factors. Further socio-economic factors related to 
higher non-adherence with immunosuppressive therapy in renal transplantation are 
social network variables 21 24 31 56 57 61. Non-adherence is associated with living alone 21 
31, being unmarried 31 56 61, or perceiving low social support 62. Analyses investigating 
the factor education remain inconclusive 19 21 24 25 31 35 57 58 60 61, as some studies did not 
find any relation with non-adherence 19 21 25 31 35 57, while others found a positive 24 62, or 
a negative one 58 60 61. Likewise, socio-economic class 21 24 61 and gender 21 23-25 31 35 51 57 
58 60 61 were not consistently related to non-adherence. In general, it can be stated that 
socio-economic factors alone, except for younger age and social isolation, show a 
limited association with non-adherence, in line with evidence from other chronic patient 
populations 14. 
2.5.2. Patient-related factors 
Patient related factors refer to the resources, knowledge, attitudes, beliefs perceptions 
and expectancies of the patient 14. Patient related factors found to be associated with 
non-adherence with immunosuppressive therapy in renal transplantation are: low self-
efficacy with medication intake 31, high levels of anxiety and hostility 60, and an 
external locus of control 57 60. External locus of control refers to patient’s perception 
that the evolution of the disease is particularly a matter of chance. Furthermore, health 
beliefs about the illness or the medication regimen such as believing that the 
immunosuppressive drugs are not needed to keep the kidney, or that intake of drugs 
may be delayed, have been found to be related to non-adherence 21 58. Knowledge 
about the regimen was positively related to non-adherence in two 25 31 out of three 
studies 25 31 56. One study investigated the predictive value of pre-transplant non-
adherence on post-transplant non-adherence, finding also a significant positive 
relationship 30, in line with the evidence showing that past behavior very well predicts 
future behavior. Although a lot of studies investigated patient related correlates of non-
adherence in renal transplant, few findings were mutually corroborated. Aside from 
replicating results, future research could focus on exploring new possible determinants, 
such as busyness and routine in someone’s life style, or engaging in health behaviors 
(e.g. vaccination). 
2.5.3. Condition- or disease-related factors 
The condition or disease related variables depression 61 and dependency on nicotine 24 
or on illegal drugs 19 24 showed a positive relationship with non-adherence, whereas 
having diabetes was related to less medication non-adherence 58, perhaps due to the 
long-time adoption of adequate health behavior. 
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2.5.4. Therapy- or treatment-related factors 
Therapy or treatment related factors such as time on dialysis, or being retransplanted 
were not associated with non-adherence 23 25 29 58 61. Three studies 59-61 out of 8 23 25 31 
57-60 found more non-adherence in patients with a longer post-transplant status, 
confirming the evidence that duration of the regimen is associated with non-
adherence. Other treatment related factors were the number of medications, a factor 
referring to the complexity of the medication regimen 25, and patients’ subjective 
experiences of the symptoms related to side effects of medication (e.g. excessive hair 
growth, moon face) 58 60 63. Two studies 21 58 out of six 21 24 35 51 58 60 detected more non-
adherence in recipients of a living donor graft, compared to cadaveric grafts. Future 
research could focus on the effect of the use of medication reminders (e.g. a pill 
organizer), changes in the medication regimen, pre-emptive transplantation, or the 
number of medication intakes per day on non-adherence. 
2.5.5. Health care system- and health care team-related 
factors 
The last category of determinants of non-adherence, health care system and health 
care team related factors has been studied far less, indicating a bias in the literature. 
Two studies investigated the effect of the insurance status on non-adherence 34 58, one 
of which found more non-adherence in blacks who were not privately insured 34. 
Another study tested and detected self-reported differences between European and US 
renal transplant patients 64. One study found non-adherence differences in the included 
centers 67. The lack of evidence about health care system and health care team related 
factors shows that the patient is implicitly seen as defaulter. As a consequence, 
opportunities for improving adherence through optimizing the health care system or 
training the health care worker remain hidden 14 65. Future research should therefore 
focus on issues such as the communication style, knowledge, and skills of the health 
care worker, on time constraints during clinical consultations, and on organization of 
the follow-up care. 
Some general remarks should be made about the studies examining determinants of 
non-adherence with immunosuppressive medication in renal transplant patients, more 
specifically about the used data analysis methods. Unlike the studies investigating the 
clinical consequences of non-adherence, determinant studies often do not mention the 
used statistical test. If they do, few report on the distributional properties of the 
adopted non-adherence operationalization. This lack of statistical background 
information for model validation jeopardizes the credibility of the presented results, 
because tests are performed requiring normally distributed data; yet, non-adherence 
measurements are in many cases highly skewed. Another statistical issue concerns the 
fact that many studies only report statistical significant findings, although a large 
amount of not mentioned candidate determinants have been tested. Even if studies 
report all the results, no study controlled for multiple testing. As a consequence, a 
significant proportion of the reported statistically significant findings were happening 
accidentally. 
  
Table 4: Studies testing determinants of non-adherence with immunosuppressive medication in renal transplant patients 
Study Description of the 
sample 
N Design Adherence 
measurement 
Determinants assessed Analysis Results: factors that were 
related to non-adherence 
Weng et al. 
2005 67 
RTX recipients with 
cadaver kidney, > 18 
years; US 
278 Pro-
spective 
cohort 
study 
One year of electronic 
monitoring. Cut off not 
mentioned 
Socio-economic: age, gender, marital & 
employment status, education, income, 
ethnicity 
Therapy related: diagnosis, HLA 
matching, initial hospital length of stay, 
delayed graft functioning, in-hospital 
rejection, previous RTX, 
immunosuppression, intake frequency, 
pre-emptive RTX 
Patient-related: transplant stress 
questionnaire, social support appraisal 
scale, center for epidemiologic research 
depression scale, multidimensional 
health locus of control scale, medical 
outcomes study short form health 
survey, medication side effects scale 
System factor: transplant center 
Stepwise 
logistic 
regression 
Transplant center (p=.003), 
intake frequency (.003) 
Butler et al. 
2004 21 
RTX recipients > 18 
years, ≥ 6 months 
post-transplant, with 
functioning graft; UK 
60 Pro-
spective 
cohort 
study 
Six week of electronic 
monitoring of Pred. 
Non-adherence is 
defined as taking < 
20% of the prescribed 
doses 
Chi²-test & 
Mann-
Whitney U 
More NA if younger age 
(p=.01), living alone 
(p=.02), having a living 
donor graft (p=.01), having 
a lower belief in the need for 
immunosuppressives 
(p<.01), scoring lower on the 
BMQ-benefits subscale 
(p<.01), having negative 
emotions linked to the 
transplant (p<.05) 
     
Socio-economic: age, gender, marital & 
employment status, education, social 
class, ethnicity, social support 
(Significant Others Scale) 
Therapy related: number of RTXs, graft 
type, time since RTX, number of 
rejections, HLA match, time on dialysis, 
donor diabetes or hypertension, 
duration of past RTXs 
Condition related: disease severity, past 
medical details, functional health status 
(SF-36), depression (revised Clinical 
Interview Schedule) 
Stepwise 
logistic 
Significant more NA in living 
donor transplants, patients 
  
Study Description of the 
sample 
N Design Adherence 
measurement 
Determinants assessed Analysis Results: factors that were 
related to non-adherence 
Patient-related: expectation about the 
RTX, illness perceptions (Illness 
Perception Questionnaire-6 subscales); 
medication beliefs (Beliefs about 
Medicines Questionnaire - 5 subscales) 
regression having a low belief in the 
need for immunosuppression 
Vlaminck et 
al. 2004 23 
RTX recipients > 18 
years old, ≥ 1 year 
post-transplant, Dutch 
speaking; on CyA; 
Belgium 
146 Pro-
spective 
cohort 
study 
Self-reported NA 
measured at inclusion, 
defined as having 
regular dose omissions 
in the past 1 year 
Socio-economic: age, gender 
Therapy related: donor age, time after 
RTX, serum creatinine 1 year post-
transplant, serum creatinine at 
inclusion, delayed graft function, 
number of acute rejections in 1st year 
post transplant, number of 
transplantations, number of HLA 
mismatches 
Patient related: perceived social support
Unknown More NA if no perceived 
social support (p=0.028) 
 
Ghods et al. 
2003 24 
RTX recipients > 1 
year post-transplant; 
95% on CyA 
(+sometimes MMF), 
5% on AZA/Pred; Iran 
 
267 Cross-
sectional 
Self-report: missing ≥ 3 
doses per month. If 
non-consecutive: minor 
NA, if consecutive: 
major NA 
Socio-economic: age, gender, marital 
status, education, socio-economic class 
Therapy related: graft type, number of 
RTXs, time since transplant, 
immunosuppressive regimen 
Condition related: opiate addiction, 
smoking, psychiatric disorders 
Unknown More NA if younger (12-70y) 
(p<.05), lower educated 
(p<.05), lower socio-
economic class (p<.005), 
heavy smoking, opiate 
addiction or psychiatric 
disorders (p<.05)  
Vasquez 
2003 25 
Adult RTX recipients 
with functioning graft; 
on CyA, Fk, Pred; US 
 
95 Retro-
spective 
cohort 
study 
Composite measure: 
Missed a dose since 
last visit or in week 
prior to survey receipt 
+ 3 successive CyA 
levels < 50 ng/ml or FK 
< 5 ng/ml in absence 
of CNI metabolism 
affecting drugs, or 
absorption problems 
Socio-economic: age, sex, race, socio-
economic status, education, patients’ 
source of funding 
Therapy related: number of 
medications, number of visits to the 
center. 
Patient related: knowledge about the 
immunosuppressives (multiple choice 
questions) 
Logistic 
regression 
Simple regression: More NA 
if lack of knowledge, higher 
number of medications taken 
(p<.05), lower number of 
visits to the center (p<.05) 
Multiple regression: Lack of 
knowledge (p<.0001) 
 
  
Study Description of the 
sample 
N Design Adherence 
measurement 
Determinants assessed Analysis Results: factors that were 
related to non-adherence 
Teixeira de 
Barros et al. 
2000 56 
RTX recipients; 
transplanted between 
1995-1997; Portugal 
113 Pro-
spective 
cohort 
study 
A self-reported dose 
omission or intake 
deviation of > 2,5h in 
≥ two 4-monthly 
evaluations over 2y 
Socio-economic: race, employment 
status, place of residence, marital 
status,... 
Therapy related: symptom experience: 
(Transplant Symptom Occurrence and 
Symptom Distress Scale) 
Patient related: knowledge (self-
developed questionnaire) 
Unknown More NA if a higher level of 
symptom occurrence 
(p=.00006) and symptom 
distress (p=.00029), if being 
single (p=.009) 
 
Isaacs 1999 
et al. 27 
RTX recipients with 
living related donor 
grafts; transplanted 
between 1988-1994; 
multi-center study of 
all patients in the US 
1086
5 
Retro-
spective 
cohort 
study 
Not stated Socio-economic: race (African, Native & 
Asian Americans, Whites, Hispanics) 
Unknown NA differences among ethnic 
groups (p<.003). NA highest 
among Asian Americans, 
lowest among Hispanics 
Raiz et al. 
1999 57 
RTX recipients >18 
years old, first 
transplant, with 
functioning graft; >12 
months post-
transplant; RTX 
between 1985-1994; 
US 
308 Cross-
sectional 
Self-report: admission 
of dose omissions  
Socio-economic: age, education level, 
gender, marital status, Medicaid status 
(indication of income), race, difficulties 
with paying immunosuppressives 
Transplant related: years since RTX, 
number of medications 
Condition related: health status (8 
subscales from the Medical Outcomes 
Study - Short Form 36) 
Patient related: intrusiveness of illness 
or treatment on life domains (Illness 
Intrusiveness Rating Scale); locus of 
control (3 subscales: Health Locus of 
Control scale); perceived social support 
(3 subscales: Social Support Appraisal 
Scale); ever having felt bothered by any 
aspect of the RTX at the center 
Multiple 
regression 
More NA if younger age, 
perceiving more limitations 
due to pain, if believing that 
chance controls health 
outcomes (= a locus of 
control subscale), if having 
felt bothered by any part of 
the RTX experience (all 
probability values <.05) 
Papajcik et 1) RTX with 77 + Case- Missing ≥ 1 of the Socio-economic: age, gender, race, t-test, More NA in younger patients, 
  
Study Description of the 
sample 
N Design Adherence 
measurement 
Determinants assessed Analysis Results: factors that were 
related to non-adherence 
al. 1999 35  functioning graft ≥ 1y 
post-transplant, with 
biopsy confirmed 
chronic rejection; 
transplanted between 
1987-1994 
2) Matched group 
without chronic 
rejection 
49 control 
study 
following tasks ≥ 5x / 
year for ≥ 2 
consecutive years: 
1. Having lab tests 
done 
2. Attending follow-up 
appointments 
3. Taking 
immunosuppressants 
education, having work 
Therapy related: graft type 
Condition related: functional status, 
Patient related: degree of happiness, 
live events, self-care behaviors 
Chi²-
test/Fisher 
exact test 
and in men 
 
Rudman 
1999 29 
RTX recipients that did 
not loose the graft in 
the first 2 months 
posttransplant; data 
gathering restricted to 
12 months; US  
374 Retro-
spective 
cohort 
study 
1. Non-adherence = 3 
missed calls in a row, 
in which the patient 
transfers his lab data 
2. Collateral report by 4 
staff members 
Therapy related: number of transplants 
received 
Correlation A positive significant 
relationship of NA 
Greenstein 
& Siegal 
1998 58 
RTX recipients > 18 
years old, with 
functioning graft; on 
CNI; 56 centers (US) 
1402 Cross-
sectional 
study 
Self-report: having 
missed ≥ 1 
immunosuppressant in 
the past 4 weeks 
Socio-economic: age, gender, ethnic 
group, country of origin, education, 
employment status 
Condition related: diabetes 
Therapy related: graft type, time since 
transplant, number of transplants, 6 
questions about dialysis, 8 symptom 
frequency related to side effects 
questions, 
Patient related: health beliefs and 4 
questions about the importance of post-
transplant drugs 
Health care system: insurance status  
Simple 
logistic 
regression 
More NA if younger age, 
having had at least some 
college education, if 
employed, having white 
collar occupation, if RTX with 
a living related donor graft, if 
longer time since RTX, not 
diabetic (p<.001), born 
outside the US, reporting 
infections (symptoms scale) 
(p<.05) 
More NA if a lower belief 
- that the drugs are needed 
to keep the kidney, 
- that the drugs should never 
be delayed, 
- that the drugs are needed 
  
Study Description of the 
sample 
N Design Adherence 
measurement 
Determinants assessed Analysis Results: factors that were 
related to non-adherence 
even if kidney is functioning 
- that the drugs stay active > 
24h (p<.001) 
     Multiple 
logistic 
regression 
More NA if: younger age, 
having white collar 
occupation (p<.05), longer 
time since RTX (p<.001), 
lower belief that drugs 
should never be delayed 
(p<.05), that drugs are 
needed even if the kidney is 
functioning well, or that 
drugs stay active >24h 
(p<.001) 
Siegal & 
Greenstein 
1997 59  
Non-adherent RTX 
recipients > 18y, with 
functioning graft; on 
CyA; 5 centers in the 
US 
96 Cross-
sectional 
Self-report: frequency 
of forgetting 
immunosuppressive 
medication in the last 4 
weeks. 
 Regression 
analysis 
Related to NA: younger age, 
longer time since transplant, 
if indicating not to take 
medications when away from 
home 
Douglas et 
al. 1996 30 
RTX recipients > 18 
years at RTX, without 
rejection due to 
technical failure or 
rejection <3 months, 
that survived >3 
months; transplanted 
between 1986-1988; 
US 
126 Retro-
spective 
cohort 
study 
Composite measure: 
documented non-
adherence in the post-
transplant medical 
chart (appointment NA, 
NA with medications, 
…) 
Patient related: documented non-
adherence in the pre-transplant 
evaluation chart (appointment non-
adherence, non-adherence with 
medications, use of illicit drugs, …) 
Spearman’s 
rho 
Non-adherence before the 
transplantation is related to 
non-adherence after the 
transplantation (rho=.33; 
p<.01) 
De Geest et 
al. 1995 31 
RTX recipients > 18 
years old, ≥ 1 year 
post-transplant, Dutch 
speaking; on CyA; 
148 Retro-
spective 
cohort 
study 
Self-report Socio-economic: age, gender, years of 
education, marital status, living alone 
Therapy related: time since 
transplantation, symptom experience 
t-test, 
Mann-
Whitney U, 
Chi²-test 
More NA: if unmarried or 
single (p=.028), if lower self-
efficacy (p=.048), if lower 
self-care agency (p=.025), if 
  
Study Description of the 
sample 
N Design Adherence 
measurement 
Determinants assessed Analysis Results: factors that were 
related to non-adherence 
Belgium (Modified Transplant Symptom 
Occurrence and Symptom Distress 
Scale) 
Patient related: self-efficacy (Long-Term 
Medication Behavior Self-efficacy Scale); 
self-care agency (Appraisal of Self-Care 
Agency Scale); knowledge of the 
regimen: self-developed instrument 
less situational-operational 
knowledge (p=.02) 
Sketris et 
al. 1994 60 
RTX recipients taking 
CyA; 2 centers in 
Canada 
361 Cross-
sectional 
Self-report: 1) taking a 
smaller or larger dose 
>1/week, 2) dose 
taking > 2 hours before 
of after indicated time 
>1/week; or 3 ) 
omitting a dose 
>1/month 
Socio-economic: age, gender, education
Condition related: perception of health 
Therapy related: time since transplant, 
graft type, number of rejection 
episodes, symptom frequency, 
immunosuppression dosage per body 
weight, delivery method, once/twice 
daily regimen, time since last visit, 
number of medications 
ANOVA & 
Chi²-test 
More NA in adolescents, 
higher educated patients, 
patients with more 
medication, with more side-
effects, over 1 year 
transplanted, that 
experienced more rejection 
episodes (all p’s <.05) 
 
Frazier et 
al. 1994 61 
RTX recipients, 
transplanted between 
1987 & 1990 
241 Cross-
sectional 
Self-report: total score 
of an 11 item scale (5 
points) assessing non-
adherence with 
medications 
Socio-economic: age, gender, marital 
status, income 
Condition related: depressive symptoms 
(Beck Depression Inventory), insulin 
dependence 
Therapy related: number of transplants, 
time since transplant 
Patient related: anxiety & hostility (Brief 
Symptom Inventory); transplant-related 
stress-issues; locus of control 
(Multidimensional Health Locus of 
Control Scale), social support (Inventory 
of Socially Supportive Behaviors), 
coping (Coping Strategies Inventory) 
Correlation 
analysis 
More NA in women, 
unmarried, younger, higher 
income recipients (p<.01). 
Also in patients previously 
transplanted (p<.01), with 
higher anxiety, hostility 
(<.001), depression (p<.01), 
stress (p<.001), patients 
believing that their health 
outcomes were due to 
chance (p<.05), and patients 
using avoidance coping 
(p<.01) 
 
Butkus et 1st cadaveric RTX 100 Retro- Composite measure: Socio-economic: ethnicity, … Unknown More NA in blacks compared 
  
Study Description of the 
sample 
N Design Adherence 
measurement 
Determinants assessed Analysis Results: factors that were 
related to non-adherence 
al. 1992 34 between 1985-1991; 
on CyA; US 
spective 
cohort 
study 
≥ 3 consecutive missed 
clinic visits, 
immeasurable blood 
CyA on 2 consecutive 
visits without another 
explanation; leaving 
hospital against advice 
Health system related: private insurance to whites, in patients without 
private insurance (but only 
within the group of blacks) 
(p<.05) 
Kalil et al. 
1992 19 
RTX surviving the 1st 
year; transplanted 
between 1976-1982; 
on AZA/Pred; US 
202 Retro-
spective 
cohort 
study 
Composite measure: 
- NA reported in the 
medical chart 
- The percentage of 
prescribed creatinine-
level measurements 
the patient transferred 
to the center. 
Socio-economic: age, family income, 
education: years of education, race, 
distance to the transplant center (within 
or further than 50 miles) 
Condition related: chemical dependency 
Unknown NA higher in patients living 
outside the metropolitan area 
(p<.01) 
Rovelli et 
al. 1989 51 
RTX recipients > 3 
months post-
transplant, 
experiencing no 
rejection < 3 months; 
RTX between 1971-
1984; US 
260 Retro-
spective 
cohort 
study 
Composite measure: 
1. Appointment NA 
2. Medication NA: 
admission of 
patients/family 
Socio-economic: age, gender, ethnic 
group 
Therapy related: graft type 
Unknown More NA in patients <20y 
compared to > 40y 
(p=.0001). Ethnic group 
differences (p=.0001): more 
NA in Hispanics and blacks 
 Same inclusion criteria, 
but RTX after 1984. 
Patients received 
adherence enhancing 
education before RTX 
196 Pro-
spective 
cohort 
study 
Same measurement 
method 
Socio-economic: age, gender, ethnic 
group 
Therapy related: graft type 
Unknown Ethnic group differences 
(p=.0001): more NA in 
Hispanics and blacks 
Abbreviations: AZA = azathioprine; CyA = cyclosporine; CNI = calcineurin inhibitor; FK = tacrolimus; MMF = mycophenolate mofetil; NA 
= non-adherence; Pred = prednison; RTX = renal transplant 
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2.6. Recommendations for future research 
This literature review provides the basis for recommendations for future research: 
1. Few studies in this literature review use the sensitive method of EM for 
measuring non-adherence with the immunosuppressive regimen. Future studies 
assessing prevalence, determinants and consequences of non-adherence should use 
EM as a prime measurement method, preferably combined with self-report, assay or 
collateral report. This triangulation of methods should provide a good basis for a 
reliable measurement. In addition, studies should state the adopted measurement 
method and accompanying operational definition of non-adherence. 
2. The statistical analysis methods could be enhanced in many studies. The applied 
statistical tests should be specified, and should not violate underlying assumptions, as 
is often the case now. Moreover, too many studies have considerable multiple testing 
problems, not only because p-values are not adapted, but also because many studies 
only report their significant results, and hence, do not mention all variables tested. 
3. In view of the exploration of determinants of non-adherence, research should 
expand to also assessing health care team and health care system related factors, as 
studies so far have been disproportionally focusing on primarily patient, socio-economic 
and treatment related factors. Moreover, the use of qualitative research or statistical 
techniques modeling the interplay of different variables (e.g. path analytic methods) 
could further enhance the understanding of the different factors influencing non-
adherence. 
4. Transplant registries and large outcome studies should include non-adherence 
as a relevant parameter to further assess the impact of non-adherence on outcome on 
a population basis. To examine the clinical consequences of non-adherence, 
prospective cohort studies need to be set up that test the effect of non-adherence 
under the newer immunosuppressive regimens. Sound economical evaluations 
exploring the economic consequences of non-adherence are needed, as the evidence 
base in this regard is limited to one study. These studies should take into account both 
costs and outcomes to allow cost-effectiveness or cost-utility analyses. 
5. This review did not include intervention studies, due to the fact that this 
research area still has to be developed. Intervention programs that target modifiable 
determinants of non-adherence, embedded in a chronic disease management program, 
should be tested in with randomized controlled methodology. 
2.7. Conclusion 
Non-adherence with the immunosuppressive regimen in renal transplantation is a 
common phenomenon with serious consequences. A deeper understanding of the 
dynamics underlying non-adherence could be achieved by further exploring its 
determinants. Emphasis should thereby be put on system factors, as these may offer 
still unknown possibilities to support patients in reaching a higher adherence level. 
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3.1. Introduction 
The introduction of electronic monitoring (EM) for assessing medication non-adherence 
has enabled researchers and clinicians to gather data about medication-taking behavior 
with unprecedented precision. EM systems use pill bottles containing a small electronic 
processor that records the date and time of each cap opening, resulting in a more 
detailed non-adherence measurement. Compared to other methods (e.g., pill counts, 
assay, self-report, collateral report, prescription refills), EM captures more of the 
dynamics of medication-taking behavior 1. Although EM has for this reason been used 
as gold-standard method for assessing medication adherence 2 3, empirical evidence 
and clinical experience suggest that several factors can jeopardize the internal and 
external validity of EM studies 4. Unbiased EM measurement depends on the fulfillment 
of at least four assumptions. The first 3 of these assumptions ensure internal validity: 
(1) correct functioning of the EM equipment, (2) correspondence between EM-bottle 
openings and actual intake of the prescribed dose, (3) and absence of an EM-
associated influence on a patient’s normal adherence behavior. The fourth assumption 
ensures external validity: use of EM does not bias the representativeness of the 
sample. This article discusses processes that might lead to a violation of these 
assumptions and describes how these assumptions were empirically tested. 
3.1.1. Assumptions underlying valid electronic medication 
adherence monitoring: internal validity 
Assumption 1. The first assumption ensuring unbiased assessment of medication non-
adherence requires that electronic monitoring equipment function properly (Figure 1). 
Quality tests of the widely used Medication Event Monitoring System (MEMS®-6, 
Aardex Ltd.) performed under different laboratory conditions revealed that, of the 
200,000 automatically generated events of 55 bottles and of the 31,740 manually 
generated events of 30 bottles, no missed, wrongly timed, or extra registrations were 
found 5 6. Moreover, exposing MEMS-6 to extreme laboratory conditions (e.g., keeping 
bottles at 60°C or at 2°C [n=12] for 6 h or submerging bottles under water for 12 h 
[n=8]) did not damage registration capacity or erase already registered events (n=12). 
Likewise, shocks (n=11) and vibrations (n=12) generated no extra events and did not 
damage subsequent registration capacity. Only a water resistance problem occurred in 
some bottles after they were subjected to unusually high atmospheric pressures 
exceeding 1.5 bar (n=13). 
Reports also exist of how MEMS performs in the field. A two-month assessment of 
eleven purposively sampled MEMS-IV bottles used in a one-year study of HIV patients 
(in which a number of bottles were suspected of being damaged) showed that EM 
registered only 97.5% of the generated events 7. Non-functional MEMS-V caps are also 
noted in an EM study in kidney transplant patients 8. The exact number of non-
functional caps, however, could not be inferred from the research report, since non-
functional caps and unused caps were grouped into one category. 
Assumption 2: The second assumption ensuring unbiased assessment of medication 
non-adherence requires that each time the patient unscrews the EM-bottle cap, he/she 
also ingests the prescribed dose immediately. Discrepancies in pill removal and actual 
ingestion time may lead to over- or underestimation of non-adherence (Figure 1). We 
defined non-adherence as disregarding the dosage (underdosing, overdosing) or timing 
(taking the medication at the wrong time) information given in a prescription.
  
Fig. 1. Overview of possible violations of the assumptions underlying internal and external validity of EM: effects on the non-adherence estimate 
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Overestimating non-adherence occurs when patients correctly ingest the 
immunosuppressive medication either from a source other than the EM bottle or from a 
supply of pills previously removed from the EM bottle 7 (see Figure 1, arrow 2.a). In 
these cases, patients can in fact be fully adherent but because EM-bottle openings are 
not registered, their adherence cannot be proven. Patients may avoid using the EM 
bottle because of practical or privacy reasons, making them reluctant to use the EM 
system outside the home 9 10. Overestimation of adherence also occurs when patients 
open the EM bottle but do not remove any pills (e.g., in a twice daily regimen, a third 
registration occurs when a patient demonstrates the EM system to friends; Figure 1, 
arrow 2.b). Phantom openings may, on the contrary, lead to underestimation of non-
adherence if a prescribed opening is registered, but no medicine is taken 11 (e.g., in a 
twice daily regimen, only one intake occurs even though 2 openings are registered; 
Figure 1, arrow 2.c). EM-bottle openings without pill removal can occur quite 
frequently. In the HIV population, 26% of patients report at least one opening of the 
EM bottle without taking medication 7. Finally, underestimation of non-adherence may 
also occur if patients ingest doses that are larger or smaller than those prescribed 
(Figure 1, arrow 2d). 
Under- or overestimation of non-adherence can, to some extent, be prevented by 
asking patients to report discrepancies between cap openings and pill intakes and 
using these reports to correct the raw EM data. Several studies have implemented this 
method, offering patients a form on which to write down occurred discrepancies 9 12. 
However, patients who are non-adherent to the medication therapy are also likely to 
keep poor records of discrepancies 13. Moreover, asking patients to keep notes might 
induce self-monitoring and thus become an adherence-enhancing intervention. 
Assumption 3. The third assumption underlying valid EM measurement requires the 
absence of an EM-induced effect on a patient’s normal or typical adherence behavior 
(Figure 1). Two pathways are important in this regard. Firstly, EM may influence 
normal intake behavior because patients cannot use medication aids like pill organizers 
as usual and, at the same time, be electronically monitored 4. Secondly, the awareness 
of being monitored may change the patient’s typical adherence habits 14. 
Using a pill organizer can increase the burden of a patient participating in an EM study, 
and lead to a lower participation to EM-studies among the pill-organizer users 4, or to 
stopping to use the pill organizer when continuing to be part of the study 15 (Figure 1, 
arrow 3.a). The problems related to combining an EM bottle and a pill organizer are 
expected to result in overestimating non-adherence (arrow 3.b). 
Support for the hypothesis that the awareness of being monitored may change a 
patient’s typical medication-taking habits comes from patient reports indicating that 
being electronically monitored influences normal intake behavior. In most cases, 
patients reported an increased adherence, seldom a decreased one 4 9 12 16-18 (Figure 1, 
arrows 3.d & 3.c). Support from sources other than these patient reports is scarce 
(Table 1). Five intervention studies examined whether administering EM 14 16 19 or 
disclosing the monitoring purpose of EM 13 20 changed a patient’s typical adherence 
behavior and one observational study examined whether non-adherence increased 
over time after having started EM 21. The results from these studies were inconclusive. 
The studies of Elixhauser et al. (1990) and Bertholet et al. (2000) confirmed that 
starting EM alters adherence behavior, while the other studies could not find any 
difference. The latter finding most probably reflected the existence of methodological 
weaknesses, rather than the absence of an EM-related intervention effect. A study 
overcoming most of the methodological flaws of currently published studies should 
include a large enough sample, evaluate a possible intervention effect at different time  
  
Table 1: Published studies testing a possible intervention effect of electronic-medication monitoring on typical medication-taking behavior 
Author & 
publication 
year 
Study 
design 
Description of the 
sample 
n EM Description of the 
intervention 
Outcome variable: 
medication adherence or 
clinical outcome 
Result 
Wagner et 
al. 2002  
RCT 
 
A community convenience 
sample of adult HIV-positive 
patients on HAART 
117 MEMS Experimental group 
received EM; control 
group did not  
Adherence measured with self-
report (4 weeks after start of 
study) using a taking 
adherence parameter a 
Less adherence (insignificant) in the 
EM group (91%) than in the control 
group (94%; p=.73) 
 Pre-post 
inter-
vention 
study  
A community convenience 
sample of adult HIV-positive 
patients on HAART 
monitored with EM 
60 MEMS EM started after 
baseline blood 
pressure 
measurement 
Adherence measured with self-
report at baseline and after 4 
weeks  
Less adherence (insignificant) after 
introducing EM (91%) compared to 
baseline (93%; p=.16) 
Bertholet et 
al. 2000  
Pre-post 
inter-
vention 
study 
A convenience sample of 
primary care/hypertensive 
clinic patients with therapy-
resistant hypertension  
69 MEMS EM started after 
baseline blood 
pressure 
measurement 
Clinical outcome: blood 
pressure evaluation after 1–2 
months 
Blood pressure was lower after EM 
(14/9 cm Hg) compared to baseline 
(16/10 cm Hg; p<.001)  
Matsui et al. 
1994  
Pre-post 
inter-
vention 
study 
A convenience sample of 
young β-thalassemia out-
patients on a new iron 
chelator 
10 MEMS The purpose of EM 
was disclosed to 
patients after ± 11 
months  
Adherence measured by EM 
using the taking adherence 
parameter ± 18 months after 
disclosure 
Greater adherence (insignificant) 
after disclosure (84%) compared to 
before (77%; p=.49) 
Yeung et al. 
1994  
Quasi-
experi-
mental 
study 
Non-equivalent study: two 
convenience samples of 
asthma patients on inhaling 
therapy 
21 MDI Intervention group 
given disclosure; 
control group not 
given disclosure 
Adherence measured by EM 
using the taking adherence 
parameter after 2–3 weeks 
from the study start 
Greater adherence (insignificant) in 
the disclosed group (81%) than in 
the undisclosed group (71%; p=.53) 
Elixhauser 
et al. 1990  
RCT  A convenience sample of 
psychiatric outpatients 
treated with lithium 
90 Blister 
package 
Experimental group 
received EM; control 
group did not 
Adherence measured by self-
reported, assay,% of expected 
prescription refills (after 2–4 
months of study start)  
Fewer expected prescription refills in 
the EM group (18%) than in the 
control group (31%; p<.01) 
Cramer et 
al. 1990  
Obser-
vational 
study 
An unspecified sample of 
patients 
24 MEMS All patients received 
EM  
Adherence measured by EM 
using the taking adherence 
parameter during the first and 
after a mean of 7 months from 
the start of the study  
No significant difference found 
before and after (79% vs. 79%). 
a Taking adherence = (number of taken pills / number of prescribed pills)*100 
Abbreviations: EM, electronic monitoring; MEMS, Medication Event Monitoring System; MDI, Metered-Dose Inhaler; RCT, Randomized 
Controlled Trial 
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points, use statistical tests properly, and adopt a non-adherence measurement method 
independent of a patient’s awareness (thus not self-report). 
3.1.2. Assumption underlying valid electronic medication 
adherence monitoring: external validity 
The fourth assumption refers to issues that might threaten the representativeness of 
the sample of an EM study. Examples include a large proportion of eligible subjects 
refusing to participate and a large proportion of patients dropping out of a study. The 
term dropout refers to patients who leave the study, who do not send their EM caps 
back to the research team, or who do not adhere to the guidelines underlying correct 
EM use (resulting in unreliable EM data). With the exception of a couple of studies that 
provided some evidence for representativeness bias, limited evidence exists concerning 
the external validity of EM studies. In one study, a smaller number of pill-organizer 
users decided to participate in EM than did non-users; the authors attributed this 
disparity to the burden of combining EM with pill organizers 4. Another study found that 
especially patients non-adherent to the medication have difficulties also to be adherent 
to the guidelines of the assessment 13. 
3.1.3. Purpose of the study 
Because no study to date has tested the four assumptions underlying valid EM 
measurement, the aim of the present study was to examine whether these 
assumptions were fulfilled when using EM in a sample of kidney transplant patients. 
More specifically, we aimed (1) to examine the accurate functioning of EM technology, 
(2) to check the correspondence of recorded EM-bottle openings with the actual intake 
of the prescribed dose, (3) to test whether EM influenced the typical adherence 
behavior of patients, and (4) to examine whether using EM biased the 
representativeness of the sample. 
3.2. Methods 
3.2.1. Design, sample, and setting 
The data for this prospective cohort study came from the Supporting Medication 
Adherence in Renal Transplantation (SMART) study 22. Patients were eligible if they had 
received their kidney transplant at least one year prior to enrollment, and if they were 
self-administering immunosuppressive medication, more than 18 years of age, German 
or French speaking, and literate. Patients were excluded if they were not mentally able 
to respond adequately to the researcher’s questions or to complete the questionnaires. 
The convenience sample consisted of patients followed up at two outpatient transplant 
clinics in Switzerland. Swiss health insurance, which is compulsory, largely covers costs 
for immunosuppressive medications. Patients are responsible for paying out-of-pocket 
expenses amounting to about 10% of costs for prescribed drugs. 
3.2.2. Variables and measurement 
We used the Medication Event Monitoring System (MEMS-5 TrackCap) to measure non-
adherence to immunosuppressive medications. The monitoring lasted three months 
and focused on one immunosuppressive drug per patient, preferably one taken twice 
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daily (cyclosporine, tactrolimus, mycophenolate mofetil). To capture the two dosing 
times of patients taking a combination of azathioprine and prednisone, both of which 
are typically prescribed once daily, we monitored the usage of both drugs. 
All patients received information about the monitoring of their medication-taking 
behavior, as requested by the ethical committee. Patients were also asked whether 
they perceived that using EM influenced their normal medication-intake behavior, and 
whether this influence changed their typical adherence to the immunosuppressives 
positively or negatively. 
All participants received verbal and written instructions on how to use the EM system. 
Instructions stressed the need to match EM-bottle openings with actual drug intakes 
and requested patients to write down deviations from this guideline on a form that 
accompanied the EM bottle. Examples of such guideline violations include accidentally 
opening the EM bottle, stopping EM bottle use for a period of time, and removing pills 
prematurely. Upon completion of the EM measurements, we integrated these patient 
notes into the uploaded EM data. 
At the end of the 3-month EM period, we used a structured interview to assess 
adherence to the EM instructions. The first goal of this interview was to detect defined 
periods of non-adherence to the EM instructions and to exclude them from the analysis 
(e.g., when a patient failed to use the EM device during the holidays for 14 days). The 
second goal of the interview was to assess the quality of the remaining data by scoring 
them according to five quality standards: (1) strict adherence to the EM guidelines (5 
points); (2) self-report indicated that the EM system was not used exactly as 
instructed, but complete notes were available (4 points); (3) self-report indicated that 
the EM system was not used exactly as instructed, but incomplete notes were available 
(3 points); (4) self-report indicated that the EM system was not used exactly as 
instructed, but no notes were available (2 points); and (5) self-report indicated that 
neither the EM bottle nor the form was used as instructed (1 point) (Figure 2). Data 
was considered to be of sufficient quality for analysis when the patient received a score 
of 3 points or higher. 
Dropped EM caps. We asked the patients to report if they dropped their EM caps to 
determine whether dropping the caps damaged the caps’ recording capacity. When the 
patients indicated on their special form that a drop occurred, we checked whether the 
recording system still functioned properly by scanning the uploaded EM data visually 
for extra recordings or for altered registration patterns. 
Operational definition of EM-measured adherence. Electronically measured non-
adherence was evaluated for each prescribed intake moment. Two binary variables 
represented the taking and timing dimensions of the patients’ non-adherence. The first 
variable indicated whether a patient omitted a dose (taking dimension). The second 
variable indicated whether the monitored inter-dose interval deviated by more than 
25% from the prescribed interval or whether the medication was taken within the 25% 
range (timing dimension). 
Other variables included in this study. To compare the characteristics of patients 
included in the EM study with those that refused to participate or dropped out, we 
measured non-adherence to the immunosuppressive therapy using self-report, 
collateral report, and blood assay. In the self-report, patients used a 7-point scale to 
score the frequency of non-adherence during the four weeks just prior to the inclusion 
interview – the scale ranged from never (0 points) to every day (7 points). This ordinal 
non-adherence variable was assessed during the inclusion interview. In the collateral 
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report, nurses and physicians involved in the follow-up care of the transplant patients 
scored non-adherence using a 3-point scale – good adherence (1 point), fair adherence 
(2 points), bad adherence (3 points). We used the mean scores of the health-care 
workers who evaluated and scored patients. With regard to the blood assay, non-
adherence was scored according to each patient’s drug trough levels at inclusion (i.e., 
of cyclosporine, mycophenolate mofetil, tacrolimus, or sirolimus). 
3.2.3. Data collection 
The study was reviewed and approved by the appropriate ethical committees, and 
patients signed informed consents. We collected data from June 2001 to January 2004. 
Four research staff members recruited the patients, collected demographic and self-
reported non-adherence data, and instructed the patients on how to use the EM 
system. After three months of electronic monitoring, participants received a letter to 
remind them to either bring back the EM device to the outpatient clinic or to send it 
back to the researchers (in a pre-stamped and pre-addressed envelope). Upon return 
of the device, we telephoned the patients and carried out a structured interview to 
assess their adherence to the EM guidelines (see Figure 2). During the interview, we 
also sought to determine how EM may have influenced the patients’ typical adherence 
behavior. We used Powerview® hard- and software to upload and adjust the EM data 
according to the patients’ notes. 
3.2.4. Data analysis 
Assumptions 1, 2 & 4 needed descriptive statistics. We calculated the prevalence of 
malfunctioning EM systems (assumption 1), the prevalence of reported cap recording 
mismatches and non-adherence to the EM system (assumption 2), and the proportion 
of pill organizer users not participating (assumption 4). We also compared tabulated 
mean values of non-EM measured adherence between participants and non-
participants/dropouts (assumption 4). 
Assumption 3 required inferential statistics. We modeled the probability of non-
adherence as a function of a patient’s exposure time to the EM system by performing 
two multiple random-intercepts logistic regression analysis, one modeling dose 
omissions and one timing non-adherence. The random-intercepts models, which we 
fitted using the nlmixed procedure in SAS® version 9.1, accounted for the repeated 
measurement structure of the data. These multiple models controlled for the variables 
"bottle volume" (1055cc, 325cc, 120cc), “the researcher who did the inclusion 
interview”, and “the self-reported perceived EM-intervention effect” (positive or not). 
For validity information on this method, see appendix 1. To get a more detailed insight 
into non-adherence over time, we also fit a generalized additive model including a 
spline smoothed function of exposure time 23. This function left the relationship 
between non-adherence and explosure time unspecified, and allowed graphical 
exploration of nonlinearities. 
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Fig. 2 Algorithm estimating a patient’s non-adherence to the EM guidelines 
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3.3. Results 
Four hundred thirteen adult renal transplant recipients visiting the outpatient clinic for 
their yearly check-up were asked to participate in the SMART study (Figure 3). Three 
hundred fifty-six accepted (86%) and 57 (14%) refused to participate in our study. Of 
the 57 patients, 28 granted us permission to obtain their demographic and clinical data 
from their medical files. Of the 356 participating patients, 291 (82%) agreed to be 
monitored electronically. The remaining 65 (18%) patients did not want to be 
monitored electronically but wanted to participate by completing the self-report 
questionnaires. Of the 291 patients who agreed to be monitored with EM, 3 (1%) 
never started, 3 (1%) did not return their EM caps, and one died (<1%). Thirty-four 
(12%) patients were excluded from the analyses because they failed to adhere to the 
EM guidelines. The final sample consisted of 250 patients, with an average age of 52.9 
years (sd=13.5; Table 2). The majority of subjects were Swiss citizens (n=208; 83.5%) 
and male (n=141; 56.6%). Immunosuppressive therapies consisted of cyclosporine 
and mycophenolate mofetil (n=71; 28.5%), cyclosporine (n=38; 15.2%), cyclosporine 
and azathioprine (n=37; 15.2%), or other combinations (n=103; 41.1%). 
 
Fig. 3. Patient-sample profile 
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Assumption 1. Sixty-one (22%) patients reported that they had dropped their EM caps. 
None of these caps registered the drop as an event, nor did the data afterwards reflect 
any visually detectable signs of damage to the recording system. One patient who 
never dropped his cap claimed to have better adherence than suggested by his EM 
data. A manual check of his cap revealed that it failed to register openings. This cap 
Examining assumptions of electronic medication monitoring 
 
51 
 
seemed to have gradually lost its registration capacity during the 3-month monitoring 
period, because all expected openings within the first two weeks of the measurement 
period were recorded, after which the event recordings declined. Although the gradual 
decline of cap function suggested a battery problem, a battery check did not reveal an 
exhausted battery. 
Assumption 2. Of the 249 patients with reliable EM data, 155 (62%) reported 
discrepancies on their form between recorded openings and actual medication intakes, 
which required 1084 corrections to the 44761 records of raw EM data (2.4 corrections, 
on average, per person). Twenty-eight percent of the corrections involved early 
decants of pills that were ingested later. The most frequently mentioned reasons 
patients gave for the discrepancies were going out, being on a trip, and having a 
meeting. Other reasons for correspondence failures were taking medication from 
another supply, phantom openings to demonstrate the EM bottle to visitors, and 
opening the wrong bottle. 
Twenty-three patients (9.2%) had defined periods of non-adherence to the EM 
guidelines. For these patients, an average of 13.6 days were excluded from the total 
monitoring period. Our sensitivity analysis showed that the average percentage of 
correctly dosed days reached 92.9% when including the defined periods, but amounted 
to 96.3% when excluding the defined periods. 
Table 2: Characteristics of the sample (n=250) 
Variable Categories Value
Age  Mean= 54 (sd=13)
Gender Male 142 (56.8%)
Living alone No  194 (77.6%)
Employed Yes  130 (52.0%)
Education until age 11/12 years 
until age 12/13–14/15 years 
until age 15/16–18/19 years 
advanced (college) 
 33 (13.2%)
118 (47.2%)
 26 (10.4%)
 73 (29.2%)
Nationality Swiss 209 (83.6%)
Immunosuppression Cyclosporine & mycophenolate mofetil 
Cyclosporine 
Cyclosporine & azathioprine 
Azathioprine & prednisone 
Azathioprine & tacrolimus 
Other combinations 
71 (28.4%)
38 (15.2%)
37 (14.8%)
18 ( 7.2%)
14 ( 5.6%)
72 (28.8%)
Monitored 
immunosuppressives 
Mycophenolate mofetil 
Cyclosporine 
Azathioprine/prednisone 
Tacrolimus 
Sirolimus 
103 (41.2%)
89 (35.6%)
19 (  7.6%)
37 (14.8%)
2 (  0.8%)
Self-reported EM 
influence on typical 
adherence 
No influence 
Positive influence 
Negative influence 
188 (76.1%)
53 (21.5%)
6 (  2.4%)
Assumption 3. The random-intercepts logistic regression analysis confirmed an increase 
in both taking (OR: 1.009; CI: 1.006-1.013) and timing non-adherence (OR: 1.007; CI: 
1.005-1.009) over time (Table 3). In addition, nonlinear regression lines showed that 
  
 
Table 3: Estimates and inferences from the multiple logistic random-intercept models predicting the chance of non-adherence 
Outcome variable Parameter Estimate Standard 
error 
Odds ratio (95% 
confidence interval) 
DF t
value
p
value
Omitted intakes Random-intercepts variance 2.845 0.445  241 6.39 <.0001
 Intercept -5.900 0.470  241 -12.54 <.0001
 Exposure 0.009 0.002 1.009 (1.006-1.013) 241 4.91 <.0001
 Bottle size 0.000 0.001 1.000 (1.000-1.001) 241 0.93 0.35
 Influence perception 0.277 0.328 1.320 (0.693-2.515) 241 0.84 0.39
 Interviewer 1 vs. interviewer 4 0.461 0.356 1.586 (0.788-3.192) 241 1.29 0.19
 Interviewer 2 vs. interviewer 4 0.011 0.365 1.012 (0.495-2.069) 241 0.03 0.97
 Interviewer 3 vs. interviewer 4 0.022 0.438 1.023 (0.433-2.417) 241 0.05 0.95
Intake variability Random-intercepts variance 3.486 0.422  241 8.26 <.0001
 Intercept -3.033 0.414  241 -7.31 <.0001
 Exposure 0.007 0.001 1.007 (1.005-1.009) 241 6.67 <.0001
 Bottle size -0.000 0.000 0.999 (0.998-1.000) 241 -2.08 0.04
 Influence perception 0.011 0.314 1.012 (0.544-1.880) 241 0.04 0.97
 Interviewer 1 vs. interviewer 4 0.704 0.340 2.022 (1.035-3.951) 241 2.07 0.04
 Interviewer 2 vs. interviewer 4 0.008 0.344 1.008 (0.511-1.988) 241 0.02 0.98
 Interviewer 3 vs. interviewer 4 0.148 0.422 1.160 (0.504-2.668) 241 0.35 0.73
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the increase in both dimensions mainly occurred during the first 5 weeks of 
monitoring (Figure 4). After day 35, the taking dimension of non-adherence 
stabilized. The average percentage of correctly dosed days was 96.7% when 
including the entire 3-month measurement period, but slightly decreased to 96.3% 
when the first 35 days were excluded. The timing dimension of non-adherence 
stabilized after about day 50. The average percentage of correctly timed intakes 
was 91.8% when including all data points, and slightly decreased to 91.4% when 
only considering the stable phase between day 50 and 75. A post hoc analysis 
identifying potential interactions between exposure to the EM bottle and perception 
of the EM-intervention effect, showed a stronger EM-intervention effect in patients 
acknowledging an intervention effect than in patients stating that they experienced 
no intervention effect (p=0.003). 
 
 
Fig. 4. This figure presents the nonlinear regression lines modeling the rise of non-
adherence over time after the start of electronic monitoring. Because nonlinear 
trends are easier to detect when axes have a linear interpretation, the Y-axis’ 
probability on non-adherence is transformed to a linear log-odds scale. The figure 
indicates that non-adherence increased until the first 35 days of electronic 
monitoring (vertical line). After 35 days, non-adherence was unrelated to exposure. 
Assumption 4. A comparison of pill organizer use in participants vs. non-
participants in the EM part of our study showed that pillbox use was more common 
among non-participants (38.5%) than among participants (25.1%). Table 4 
compares non-EM adherence measurements of participants and non-
participants/dropouts. The table shows that, although expected, dropouts did not 
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have a lower adherence to the immunosuppressive therapy than did participants. 
The same can be said of the non-participants: the data counterintuitively 
suggested slightly higher immunosuppressive blood assay values among the non-
participants. This pattern remained the same when analyzing those who did not 
use a pill organizer (data not shown). 
 
Table 4: Comparisons of alternative adherence measures between participants and 
non-participants and between participants with reliable EM data and participant 
dropouts 
 Variable Subgroups 
Non-
participants 
Non-participants
 
Participants
 mean sd n mean sd n
 Self-report (1-7) 0.15 0.44 65 0.16 0.49 284
 Collateral report, Center 1 (1-3) 1.10 0.31 35 0.97 0.30 164
 Collateral report, Center 2 (1-3) 1.15 0.42 20 1.19 0.44 99
 Assay: cyclosporine (mmol/l) 117 56 50 113 54 191
 Assay: tacrolimus (mmol/l) 8.9 5.8 21 7.6 2.8 44
 Assay: sirolimus (mmol/l) 14.8 7.2 5 10.1 6.2 15
 Assay: mycophenolate mofetil 
(mmol/l)
3.5 1.6 41 3.1 2.0 122
Dropouts Non-adherers to the 
EM guidelines
Adherers to the EM-
guidelines
 mean sd n mean sd n
 Self-report (1-7) 0.25 0.73 36 0.15 0.45 244
 Collateral report, Center 1 (1-3) 1.15 0.50 24 0.94 0.25 138
 Collateral report, Center 2 (1-3) 1.35 0.66 12 1.17 0.40 87
 Assay: cyclosporine (mmol/l) 122 103 125 112 43 164
 Assay: tacrolimus (mmol/l) 7.3 3.8 5 7.6 2.7 39
 Assay: mycophenolate mofetil 
(mmol/l)
3.5 2.5 17 3.0 1.8 101
 
3.4. Discussion 
This study examined four assumptions underlying the valid electronic measurement 
of medication non-adherence, which, if violated, might threaten the external 
and/or internal validity of EM studies. 
Assumption 1. We identified one EM device that had stopped recording cap 
openings during the study. Although previous laboratory test reports from Aardex, 
the company that markets MEMS, did not mention failures, our finding confirms 
literature reports that EM devices used in studies can be damaged 8 23. Admittedly, 
the Aardex report dealt with the newer MEMS-6 monitors, not the MEMS-5 
monitors used in our study. MEMS-6 mainly differs from MEMS-5 in its data upload 
technology, otherwise MEMS-6 is comparable to its predecessor in most of its other 
components (www.aardex.ch; accessed September 6, 2005). The existence of a 
non-registering cap shows that overestimating non-adherence is possible for 
patients who have damaged caps that remain undetected. A systematic check of 
the recording system before and after a monitoring period is therefore advisable 
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(M-P Schneider, PhD, University of Lausanne, personal communication, Basel, April 
18, 2005). 
Assumption 2. The present study revealed that EM registrations often do not 
correspond to the actual ingestion of the monitored medication. A recent study of 
HIV patients came to the same conclusion, finding that 36% of patients failed to 
use their EM bottles continuously during a one-year monitoring period, 38% of 
patients used their EM bottles only on occasion, and 3% of patients always 
removed more than one dose per EM-bottle opening 7. These percentages confirm 
that mismatches between EM-bottle registrations and ingestion are common and 
that non-monitored periods often occur. We showed that negating non-monitored 
periods can result in a bias in the prevalence of monitored periods, as illustrated by 
our sensitivity analysis. We overestimated non-adherence by 3.4% when we 
included the non-monitored periods into our analyses of data obtained during the 
3-month monitoring period. The overestimation would have probably been even 
larger if the Powerview analysis software we used for uploading and correcting the 
EM data allowed us only to export the uncorrected registrations instead of those 
we corrected using the patients’ notes. Also, the discrepancy will probably be larger 
in populations with higher non-adherence levels. 
Better correspondence between event registration and pill ingestion may be 
achieved by improving the way MEMS-6 measures adherence. An often mentioned 
drawback of MEMS is its impracticality 7; thus, a more practical, easy-to-use system 
may increase EM use outside of the home. Recent efforts are being made in this 
regard in that several companies have started to market EM-blister packs: Bang & 
Olufsen Medicom’s IDAS® (http://www.medicom.bang-olufsen.com), IMC’s Med-ic® 
(http://med-ic.biz), and MeadWestvaco’s Cerepak® (http:// 
www.meadwestvaco.com). 
Assumption 3. Testing the third assumption revealed that EM influenced adherence 
behavior. We detected an initial increase of non-adherence, and believe that this 
increase reflects the waning of the adherence-enhancing effect of introducing EM 
in patients' daily life. To assess patients' normal level of adherence, studies should 
examine presence and duration of an intervention effect using longitudinal analysis 
techniques 24. Traditional analysis approaches, using period prevalence parameters 
like "the percentage of prescribed medications that are taken", are limited with 
regard to analysis of detailed time-dependent evolutions. Moreover, their often J-
shaped distributions force researchers to rely on simple nonparametric tests 25. 
Given that the found intervention effect lasted more than one month, the validity 
of EM studies of one month or less can be questioned. Longer monitoring periods 
are probably less prone to bias, as shown by the fact that we only found minimal 
differences in period prevalences including the intervention period compared to 
prevalences excluding it. 
Assumption 4. We found little evidence of compromised external validity in this 
sample of renal transplant patients. Our study indeed confirmed previous research 
that found less willingness to participate among pill-organizer users 4, but failed to 
confirm the hypothesis that patients who did not adhere to EM guidelines display 
higher medication non-adherence than patients who did adhere to the guidelines 
13. This does not necessarily mean that there was no difference: measurement 
error coming from small sample sizes, low sensitivity of non-EM non-adherence 
assessment 1, and probably also of the EM-data quality assessment, may have 
blurred existing differences. Few conclusions can be made from the blood assay 
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data showing that values tended to be higher in non-participants compared to 
participants. The differences were very small compared to their variability and not 
confirmed by self-report or collateral report data. 
3.5. Conclusion 
This study shows that electronic monitoring of medication adherence, today's most 
sensitive method of measuring medication intake, can be further improved by 
fulfilling methodological requirements, such as the four assumptions discussed in 
this article: (1) A systematic functionality control of the EM system before and after 
use is indicated; (2) assessment of adherence to the EM guidelines should be 
incorporated in each EM study, and a form should be used on which patients can 
register deviations from the guidelines; (3) each EM study should examine 
intervention effects and estimate potential biases; and (4) further research 
examining the sample representativeness in EM studies is needed. Meeting these 
methodological standards may put EM on an even higher plane, helping it to really 
achieve its gold-standard aspirations. 
Reference list 
1.  Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of 
multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 
2001;134(10):968-77. 
2.  Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance 
with medication regimens. Drugs 1995;49(3):321-7. 
3.  Chaisson RE, Barnes GL, Hackman J, Watkinson L, Kimbrough L, Metha S, et al. A 
randomized, controlled trial of interventions to improve adherence to isoniazid therapy 
to prevent tuberculosis in injection drug users. Am J Med 2001;110(8):610-5. 
4.  Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of 
electronic adherence monitoring in an HIV clinic. Ann Pharmacother 2001;35(9):1010 
5.  Results summary for hardware tests 1.0. Sion: Hexalog s.a., 2004. 
6.  MEMS 6: one year manual test of MEMS 6. Sion: Hexalog s.a., 2004. 
7.  Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic 
monitoring devices to measure antiretroviral adherence: practical considerations. AIDS 
Behav 2005;9(1):103-10. 
8.  Weng FL, Israni AK, Joffe MM, Hoy T, Gaughan CA, Newman M, et al. Race and 
electronically measured adherence to immunosuppressive medications after deceased 
donor renal transplantation. J Am Soc Nephrol 2005;16(6):1839-48. 
9.  Deschamps AE, Graeve VD, van Wijngaerden E, De Saar V, Vandamme AM, Van 
Vaerenbergh K, et al. Prevalence and correlates of nonadherence to antiretroviral 
therapy in a population of HIV patients using Medication Event Monitoring System. 
AIDS Patient Care STDS 2004;18(11):644-57. 
10.  Dunbar-Jacob J, Sereika S, Rohay JM, Burke LE. Electronic methods in assessing 
adherence to medical regimens. In: Krantz D, Baum A, editors. Technology and 
methods in behavioral medicine. Mahwah, NJ: Lawrence Erlbaum Associates, 1998:95-
113. 
11.  Burke LE. Electronic measurement. In: Burke LE, Ockene IS, editors. Compliance in 
Healthcare and Research. Armonk: Futura Publishing Co., 2001:117-138. 
12.  De Geest S, Abraham I, Moons P, Vandeputte M, Van Cleemput J, Evers G, et al. Late 
acute rejection and subclinical noncompliance with cyclosporine therapy in heart 
transplant recipients. J Heart Lung Transplant 1998;17(9):854-63. 
13.  Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G. Critical comparison of 
novel and existing methods of compliance assessment during a clinical trial of an oral 
iron chelator. J Clin Pharmacol 1994;34(9):944-9. 
Examining assumptions of electronic medication monitoring 
 
57 
 
14.  Elixhauser A, Eisen SA, Romeis JC, Homan SM. The effects of monitoring and feedback 
on compliance. Med Care 1990;28(10):882-93. 
15.  Wagner GJ. Does discontinuing the use of pill boxes to facilitate electronic monitoring 
impede adherence? Int J STD AIDS 2003;14(1):64-5. 
16.  Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or 
intervention? HIV Clin Trials 2002;3(1):45-51. 
17.  Reddel HK, Toelle BG, Marks GB, Ware SI, Jenkins CR, Woolcock AJ. Analysis of 
adherence to peak flow monitoring when recording of data is electronic. BMJ 
2002;324(7330):146-7. 
18.  Fulmer TT, Feldman PH, Kim TS, Carty B, Beers M, Molina M, et al. An intervention 
study to enhance medication compliance in community-dwelling elderly individuals. J 
Gerontol Nurs 1999;25(8):6-14. 
19.  Bertholet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective 
monitoring of compliance is important in the management of hypertension. J Clin 
Hypertens (Greenwich) 2000;2(4):258-262. 
20.  Yeung M, O'Connor SA, Parry DT, Cochrane GM. Compliance with prescribed drug 
therapy in asthma. Respir Med 1994;88(1):31-5. 
21.  Cramer JA, Ouellette VL, Mattson RH. Effect of microelectronic observation on 
compliance. Epilepsia 1990;21(5):617-618. 
22.  De Geest S, Denhaerynck K, Schäfer-Keller P, Bock A, Steiger J. Supporting Medication 
Adherence in Renal Transplantation - the SMART study. Swiss Medical Weekly In press. 
23.  Hastie T, Tibshirani RJ. Generalized Additive Models. London: Chapman & Hall, 1990. 
24.  Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized 
treatments. Control Clin Trials 1997;18(3):187-203. 
25.  Dunbar-Jacob J, Foley S. A historical overview of medication adherence. In: Dunbar-
Jacob J, Erlen J, Schlenk E, Stilley C, editors. Methodological issues in the study of 
adherence. Pittsburg: School of Nursing, 2005. 
 
  
Prevalence and risk factors of non-adherence  
 
59 
 
4. PREVALENCE AND RISK FACTORS OF NON-ADHERENCE WITH 
IMMUNOSUPPRESSIVE MEDICATION IN KIDNEY TRANSPLANT 
PATIENTS 
Kris Denhaerynck, Jürg Steiger, Andreas Bock, Petra Schäfer-Keller, Susanne Köfer, 
Nicole Thannberger, Sabina De Geest  
 
In re-review:  American Journal of Transplantation  
 
 
Prevalence and risk factors of non-adherence  
 
60 
 
4.1. Introduction 
Receiving a kidney allograft entails a life-long intake of immunosuppressive medication 
to prevent rejection of the transplanted kidney. Although strict adherence to the 
immunosuppressive drug therapy is crucial to keeping the kidney well functioning, 
recipients do not always perfectly adhere to the agreed regimen 1. Studies that 
electronically monitor medication intake behavior of recipients, using microchip fitted 
pill bottles 2, show that adult kidney transplant patients are non-adherent to their 
immunosuppressive therapy in 3% to 7% of the monitored days 3-5. Non-adherence in 
kidney transplant is associated with an increased number of late acute rejections, late 
kidney graft failure 3 6-8, increased health care costs 9, and has been suggested 10 as a 
possible contributing factor of the recently observed stagnation of long-term survival of 
kidney grafts 11 12.  
Improving long-term outcomes in kidney transplantation may be achieved by 
enhancing adherence to the immunosuppressive therapy of patients at risk. 
Unfortunately, limited evidence is available about risk factors of non-adherence to 
immunosuppressives in kidney transplant patients. Of all possible risk factors, 
categorized by the WHO into the classes ‘socio-economic’, ‘patient-related’, 
‘condition/disease-related’, ‘therapy/treatment-related’, or ‘health care system/health 
care worker-related’ factors 13, only socio-economic variables have been extensively 
studied in adult kidney transplant patients 1. Frequently studied socio-economic risk 
factors for non-adherence with the immunosuppressive regimen are ‘younger age’ 14-22 
and ‘being less imbedded in a social network’ (i.e. being unmarried, living alone, 
having no employment) 14 18 21 23 24. However, in contrast to many risk factors in other 
categories, socio-economic factors are often of limited use to clinicians because of their 
relatively unmodifiable nature. Moreover, many show inconsistent relationships to non-
adherence (e.g. education) 1. 
Self-efficacy 23 and erroneous health beliefs 18 25 are two examples of clinically valuable 
patient-related risk factors. Self-efficacy refers to a person’s confidence in mastering a 
specific task 26, and plays a central role in initiation and persistence of human behavior 
26 27. Health beliefs refer to a recipient’s belief system regarding disease and therapy, a 
synthesis of information coming from previous experience, cultural background, and 
communication with significant others and health care authorities 28. Other patient-
related factors that are related to medication taking behavior in kidney transplant 
patients are health behaviors such as smoking or alcohol use 15 29. The factor 
busyness/routine in life-style, which has been studied in HIV and arthritis population 30 
31, could also be a risk factor in kidney transplantation. 
Also of clinical interest are factors related to a patient’s condition or therapy. Tested 
and found to be associated to non-adherence in kidney transplantation are higher 
symptom experience 5 18 20 24, more previous rejections 20, longer time since 
transplantation 19 20, having received a graft from a living (related) donor 14 18 32, and 
depression 15 21. Suggested relevant factors but not yet appropriately tested in kidney 
transplantation are the use of medication aids 33, treatment complexity and changes 13, 
and pre-emptive transplantation 14.  
A last category, health care system/worker-related factors, has been studied to a lesser 
extent. Only a small number of system-related risk factors are studied. Having no 
health insurance is for instance related to non-adherence 34. Other studies found that 
non-adherence varies among centers 5 35.  
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Although some risk factors for non-adherence in kidney transplantation have been 
identified, important methodological shortcomings of the cited studies prevent firm 
conclusions 1. The majority of studies have a important methodological shortcomings, 
such as multiple testing problems, or the use of self-report to measure non-adherence, 
which is known to have less sensitivity compared to other methods (e.g. electronic 
monitoring of medication intake) 36. Moreover, many possibly important risk factors of 
non-adherence already tested in other populations (HIV, heart transplantation) have 
not been extensively examined in kidney transplantation. 
The aim of this study was therefore do a comprehensive assessment and testing of risk 
factors of non-adherence. To maximize the power of this study and enhance the 
validity of its results, we measured non-adherence by sophisticated electronic 
monitoring technology. 
4.2. Methodology 
4.2.1. Design, sample and setting 
This prospective study is part of the Supporting Medication Adherence in Renal 
Transplantation (SMART) project 37 38. The study’s convenience sample included adult 
kidney transplant recipients older than 18 years, who were at least one year 
transplanted, who managed their immunosuppressives intake independently, were 
German or French speaking, literate, and who were followed up at one of the two 
included outpatient transplant clinics in Switzerland. Exclusion criteria were lack of 
mental acuity to answer the questions or inability to read. Swiss health insurance, 
which is compulsory, largely covers costs for immunosuppressive medications. Patients 
are responsible for paying out-of-pocket expenses amounting to about 10% of costs 
for prescribed drugs. 
4.2.2. Variables and measurement 
4.2.2.1. Non-adherence measurement 
Electronic monitoring of non-adherence. We assessed non-adherence with 
immunosuppressive medication by electronic monitoring, using the MEMS®-V TrackCap 
system (Aardex, Ltd.). Provided that certain validity issues are taken into account 37, 
EM has proven to be the most sensitive and valid measurement method for assessing 
non-adherence, able to detect minor deviations from the prescribed treatment regimen 
in clinically stable patients 36. Moreover, EM provides information on patients’ daily 
medication intake dynamics. 
Validity of the EM measurement. To ensure the validity of the EM measurement, we 
excluded the first 35 days of the EM measurement period from the analyses because of 
a detected intervention effect of starting up EM 37. We also asked patients to write 
down actual medication intake times on a special form when cap openings did not 
correspond to medication intake. The form notes allowed us to correct mismatches 
between registrations and actual dose intakes. We also assessed adherence to the 
guidelines of correct EM and form use in a telephone interview at the end of the 
monitoring period. The telephone call allowed us to exclude data of time periods in 
which a patient was not adherent to the EM guidelines. Patients who made no 
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continuous use of the EM-bottle and did not notify this on the form, were excluded 
from the study. 
Definition of the EM variables. Variables for describing period prevalences and for 
doing inferential analyses were calculated differently. 
The EM period prevalence parameters were 39: (1) taking adherence, the percentage of 
prescribed doses that were taken; (2) dosing adherence, the percentage of days with 
correct dosing; (3) timing adherence, the percentage of inter-dose intervals within 
25% of the prescribed interval; and (4) drug holidays, the number of periods without 
drug intake that exceeded 48h in a once daily, or 24h in a twice daily regimen, 
standardized over 100 monitored days. The assessment period started 35 days after 
monitoring the first morning dose and ended three months later; or earlier when the 
patient dropped out. We defined a day as starting at 3:00 am and ending at 2.59 am.  
The outcome variable in the inferential analyses consisted of a longitudinal binary 
sequence representing patients’ non-adherence status on each prescribed intake 
moment. Omitted doses or wrongly timed doses were considered as non-adherence. A 
dose was considered as rightly timed if the interval with the previous dose did not 
deviate more than 25% from the prescribed interval. Excess dosing was not taken into 
account, as previous research showed that only a minority of EM-detected 
overconsumption really corresponds to overdosing 40. 
4.2.2.2. Measurement of risk factors of non-adherence 
We explored selected risk factors of non-adherence from all five dimensions of the 
WHO classification of non-adherence risk factors. Socio-economic factors retrieved 
from the medical files were age, gender, and nationality; those assessed by structured 
interview were living alone/together, being employed/unemployed, the perception of 
adequacy of the financial situation to cover costs of medications (on a 4-point scale 
from more than enough to not enough money), and educational level (measured by a 
4-points ordinal variable reflecting the age until which patients went to school: until 
11/12, 14/15, 18/19 years, or longer). Received social support with medication taking 
was assessed using an 8-item scale that scored how often it happened in the past 
month that a patient received social support from others (e.g. someone helped 
preparing the medication) 41. Unrotated principal component analysis revealed 
unidimensionality among 7 items that loaded at least 0.44 on the first factor. One item 
(“Was there someone who went to the pharmacy for you to get your medication?”) 
only loaded 0.27 on the first component, indicating that it measured a different aspect 
of social support. We therefore considered this item as a separate variable in the 
analyses and calculated an average total score on the remaining seven items. The 7-
item scale had a Cronbach’s alpha of 0.70.  
Patient-related factors explored by structured interview in this study were vaccination 
status (influenza and pneumonia), current smoking status (yes/no), frequency of 
alcohol use during the last month (on a 6-point scale ranging from daily to never), use 
of complementary medicine (e.g. homeopathy, St. John’s worth, Chinese medicines), 
and the day of the week. We also measured self-reported non-adherence by asking 
patients in a non-threatening, non-accusatory way how frequently they did not take 
their immunosuppressive medication in the past four weeks 18. They could answer on a 
7-point scale ranging from never to every day.  
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Multi-item validated self-report instruments were used to measure self-efficacy with 
medication taking 42, illness representations 18, business and routine in life style 31 43, 
and coping style 44. 
Self-efficacy was measured using the Long-Term Medication Behavior Self-Efficacy 
scale 42, a 27-item instrument with a 5-point scale ranging from 1 (=little confidence) 
to 5 (=strong confidence). The scale has been validated in both transplant and other 
populations as being a unidimensional instrument showing predictive validity 45. The 
instrument’s unidimensionality was reconfirmed in this study; an unrotated principal 
component analysis showed that the first component, on which all items loaded at 
least 0.44, accounted for 41% of the variance. We used the average score as a 
measure of self-efficacy. 
Illness representations related to medication taking was assessed by a scale developed 
by Greenstein and Siegal 18, consisting of 10 beliefs about immunosuppressive drugs 
(e.g. “I will only be able to keep my kidney if I take my post transplant drugs”). For 
each health belief statement, patients scored their level of agreement on a 5-point 
scale ranging from ‘completely disagree’ to ‘completely agree’. An unrotated principal 
component analysis revealed that the items hardly shared common information: 
absolute component loadings on the first component ranged from |0.20| to |0.65|, 
with an average of |0.41|. Because of the lack of unidimensionality, we considered 
each item as a separate variable in the analyses.  
Coping was assessed by the Utrecht Coping List (UCL) 44, a 47-item instrument 
measuring a person’s coping style when faced with difficult life situations. Patients 
scored on a scale from 1 (=seldom or never) to 4 (=very often) the frequency of a 
specific coping behavior. The scale is meant to measure seven different styles: 1) 
active coping (taking action to solve a problem), 2) avoidance coping (avoiding difficult 
situations or resigning), 3) seeking social support, 4) passive coping (waiting for things 
to change), 5) expression of emotions (showing emotions but not directly approaching 
a problem), 6) reassuring coping (overcoming a problem by thinking about bigger 
problems), and 7) palliative coping (taking action to soothe the discomfort of a 
problem) 44. An examination of the internal structure of the instrument using varimax 
rotated principal component analysis, revealed that the last component (palliative 
coping) consisted entirely of items that cross-loaded on other components. We 
therefore omitted this component from the analysis and refined the six remaining 
subscales by deleting items that loaded on more than one component at the same 
time. The six subscales had acceptable internal consistency, as shown by the 
respective Cronbach’s alpha values (0.80, 0.62, 0.84, 0.76, 0.50, and 0.70), which 
made it possible to calculate mean scores for each subscale. 
Life style was assessed by the ACQ Busyness Scale, a 13-item 5-point self-report 
instrument presenting statements related to the dimensions busyness and regularity in 
one’s daily life 31 43. A varimax rotated principal component analysis confirmed the 
existence of two dimensions: ‘busyness’ (the items 1 to 9) and ‘routine’ (the items 10-
13), for which the Cronbach’s alpha values were 0.85 and 0.76, respectively. The 
variables busyness and routine were calculated by averaging the items in each of the 
dimensions. 
As condition-related factors, we extracted two variables from the medical file, namely 
body mass index and Charlson comorbidity index (omitting the age aspect, to prevent 
collinearity with the already included variable age). We also measured depressive 
symptomatology by self-report using the Beck Depression Inventory 46 47, a 21-item 4-
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points self-report scale assessing the emotional, cognitive and physical symptoms of 
depression. An unrotated principal component analysis confirmed the unidimensionality 
of the scale by showing one distinct component on which all items loaded at least 0.40. 
The scale’s Cronbach’s α was 0.88, which allowed us to calculate a mean score over all 
items. 
The therapy-related factors extracted from the medical file were graft type (cadaver, 
living-related [e.g. a sibling], or living-unrelated donation [e.g. a spouse]), dialysis 
mode (peritoneal or haemo-dialysis), total time spent on dialysis, pre-emptive 
transplantation (yes/no), the number of received transplants, the number of prescribed 
medications, prescription changes, the regimen (once or twice daily), and medication 
intake time (morning or evening). We also measured by structured interview whether 
patients used medication aids (pillbox, alarm clock, beeper, calendar, putting the 
medication conspicuously on one or different places).  
Symptom experience was measured with the Modified Transplant Symptom Occurrence 
and Symptom Distress Scale 48 49, a self-report instrument consisting of 45 symptoms 
measuring both symptom occurrence and symptom distress. Patients scored the 
occurrence of symptoms on a 5-point scale (0 to 4), and the accompanying distress on 
a separate and visually distinct 5-point scale (1 to 5). Distress scores were deleted if 
symptom occurrence was indicated as not present (=0). Because an unrotated 
principal component analysis on the occurrence items showed that the average 
absolute component loading only reached |0.38|, and that the shared variance among 
the items was only 16%, we considered each item as a separate variable in the 
analyses, an approach that differed from previous studies 5 18 20 24. 
Health care system/health care worker-related factors assessed in this study were the 
number of clinic visits the patient had during the 3 months study period, the number of 
days before the next follow-up visit (both retrieved from the medical files)50, and 
outpatient center (Basle or Aarau).  
4.2.3. Data collection 
The study was reviewed and approved by the appropriate ethical review boards. We 
collected data from June 2001 to January 2004. Four research staff members recruited 
the patients, collected demographic and self-reported non-adherence data, instructed 
the patients on how to use the EM system, and obtained signed informed consents. 
Patients took the self-report questionnaires home, were asked to complete them and 
send them back in a pre-stamped and pre-addressed envelope. After three months of 
electronic monitoring, participants received a letter to remind them to either bring back 
the EM device to the outpatient clinic or to send it back to the researchers. Upon return 
of the device, we telephoned the patients and carried out a structured interview to 
assess their adherence to the EM guidelines. During the interview, we also sought to 
determine how EM may have influenced the patients’ typical adherence behavior. We 
used Powerview® hard- and software to upload and adjust the EM data according to 
the patients’ notes. 
4.2.4. Statistical analysis 
We checked the distribution of the non-adherence period prevalence parameters, and 
calculated the following central tendency and variance parameters: average, median, 
inter-quartile range, and range. Each risk factor’s relationship with non-adherence was 
Prevalence and risk factors of non-adherence  
 
65 
 
separately tested using simple random-intercept logistic regression analysis. To prevent 
the accumulation of type I errors among the logistic regression analyses, we adapted 
all p-values by a method that holds the expected proportion of type I errors among the 
rejected null hypotheses at 5% 51. The tables presenting the results contain all 
uncorrected (p) significant variables, with their multiple testing corrected estimates and 
inferences (q). Variables that were significant after correction for multiple testing were 
put into a multiple random intercept logistic regression model. Because, as in a lot of 
behavioral research, many risk factors might be correlated with each other, we 
checked for possible multi-collinearity by calculating the variance inflation factor of the 
variables in the multiple regression model. All analyses were done in SAS 9.1. 
4.3. Results 
4.3.1. Sample characteristics 
Four hundred thirteen adult renal transplant recipients visiting the outpatient clinic for 
their yearly check-up were asked to participate in this study, of which 86% (N=356) 
agreed to take part with the questionnaire part and 291 to be monitored electronically 
(Figure 1). Of these 291 EM patients, 3 (=1%) never started EM, 3 did not return the 
EM cap, 1 (<1%) died in the beginning of the study, and 34 (=11.7%) were excluded 
from the analyses because of non-adherence to the EM guidelines. The final sample 
(N=249) had a mean age of 53.5 years (sd=12.7), consisted of 83.6% Swiss citizens 
(n=208), and 58.6% males (n=207; Table 1). Monitored immunosuppressive therapies 
were mycophenolate mofetil (n=102; 41.0%), cyclosporine (n=53; 35.7%), 
azathioprine/prednisone (n=19; 7.6%), tacrolimus (n=37; 14.9%), and sirolimus (n=2; 
0.8%). 
 
Figure 1: Sample profile 
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Table 1: Demographical characteristics of the sample (n=249) 
Variable Categories Value  
  Mean (SD) 
Age  53.6 (12.7) 
   
  Frequency (%) 
Gender Male 141 (56.6%) 
Living alone No 193 (77.5%) 
Employed Yes  129 (51.8%) 
Education until age 11/12 years 
until age 12/13–14/15 years 
until age 15/16–18/19 years 
advanced (college) 
 33 (13.3%) 
117 (47.0%) 
 26 (10.4%) 
 73 (29.3%) 
Nationality Swiss 
Non-Swiss 
208 (83.5%) 
 41 (16.5%) 
Monitored 
immunosuppressives 
Mycophenolate mofetil 
Cyclosporine 
Azathioprine/prednisone 
Tacrolimus 
Sirolimus 
102 (41.0%) 
89 (35.7%) 
19 (  7.6%) 
37 (14.9%) 
2 (  0.8%) 
Number of intake 
times per day 
Once daily regimen 
Twice daily regimen 
Other regimensRegimen changes 
during the study 
8 (  3.2%) 
235 (94.4%) 
 3 (  1.2%) 
3 (  1.2%) 
4.3.2. Prevalence of (non-)adherence 
The EM based period prevalence parameters showed a mean taking adherence of 98% 
(range: 47-110%; Table 2), a mean dosing adherence of 96% (range: 23-100%), and 
a mean timing adherence of 92% (range: 18-100%). The mean number of drug 
holidays standardized per monitored 100 days was 1.1 (range: 0.0-29.1). Inter-quartile 
ranges show that a substantial number of patients had low non-adherence. In the case 
of timing adherence for instance, it can be calculated from the median and inter-
quartile range that 25% of the patients took less than 92.1% of their pills at the right 
time. 
4.3.3. Risk factors of (non-)adherence 
Table 3 presents the statistically significant results of the simple modeling. Significant 
risk factors after correction for multiple testing were: younger age (OR=0.96; q=0.02), 
male gender (OR=0.37; q=0.02), low self-efficacy (OR=0.24; q=0.02), high self-
reported non-adherence (OR=4.34; q<0.001), busy life style (OR=2.3; q=0.03), 
symptom distress with spots in the face or on the back (OR=1.69; q=0.04), and having 
a graft from a living-related person (OR=2.88; q=0.02). Also, non-adherence was the 
lowest on Monday, the highest on Sunday and increased during the days in between 
(OR=1.04; q=0.02) in a gradual way, as was shown in an additional exploratory 
analysis. Borderline significant and clinically important (OR=0.37) is that using a pillbox 
was related to adherence. 
  
Table 2: Period prevalence parameters measured by electronic monitoring 
Variable Definitions  Sample Mean Std Median Iqr Min Max 
Taking adherence (number of taken doses / number of prescribed doses)*100 249 98.4%   5.1 100.0 1.3 46.5 110.2 
Dosing adherence (number of days with correct dosing / number of days monitored)*100 249 96.2%   8.7 100.0 3.6 22.8 100.0 
Timing adherence (number of correct inter-dose intervals defined as the prescribed inter-
dose interval ± 25% / number of openings)*100 
249 91.9% 15.1   98.1 7.9 18.2 100.0 
Drug holidays The number of drug holidays per 100 monitored days. (*) 249 1.1 days   3.2     0.0 1.1   0.0   29.1 
Abbreviations: n = sample size; std = standard deviation; iqr = inter-quartile range; min = lowest value in the sample; max = highest value 
(*) drug holiday = no medication intake for > 48 hours in a once (n=3) and > 24 hours in a twice daily regimen  
Table 3: Results of the simple mixed logistic regression analysis 
Category Variable  More non-adherence … OR (95% CI) df t p q  
Socio- Age if younger 0.96 (0.94 - 0.99) 245 -3.18 0.002 0.024 * 
economic Gender if male 0.37 (0.20 - 0.68) 246 -3.23 0.001 0.024 * 
 Education if higher educated 1.44 (1.09 - 1.90) 246  2.58 0.011 0.073  
Patient  Self-efficacy with medication taking if lower self-efficacy 0.24 (0.11 - 0.55) 243 -3.43 0.001 0.024 * 
related Self-reported non-adherence if more self-reported NA 4.34 (2.38 - 7.91) 241  4.81 0.000 <.001 * 
 Busyness in life style when busy 2.30 (1.33 - 3.97) 242  2.99 0.003 0.030 * 
 Belief: Advantages of having a kidney outweigh the problems 
that accompany the post transplant drugs  
when believing this 1.39 (1.03 - 1.87) 238  2.14 0.033 0.124  
 Belief: I agree that personal knowledge about the own body 
should be taken into account when decisions are made about 
the amount of immunosuppressives to be taken  
when believing this 1.29 (1.05 - 1.58) 235  2.48 0.014 0.076  
 Belief: My kidney is functioning so well that I do not need the 
post-transplant drugs  
when believing this 1.63 (1.10 - 2.42) 241  2.42 0.016 0.082  
 Coping: passive if more of this coping style 2.05 (1.09 - 3.86 ) 240  2.23 0.027 0.117  
 Coping: expression of emotions  if more of this coping style 1.94 (1.06 - 3.54) 239  2.17 0.031 0.122  
 Vaccination when not vaccinated 0.46 (0.22 - 0.97) 243 -2.04 0.042 0.126  
 Frequency of alcohol intake (1-6) when frequent alcohol intake 1.25 (1.05 - 1.50) 240  2.47 0.014 0.076  
Therapy  Graft type (cadaveric vs. living-related) if living-related 2.88 (1.47 - 5.64) 245  3.09 0.002 0.024 * 
  
Category Variable  More non-adherence … OR (95% CI) df t p q  
related Using a pillbox if not using this aid 0.37 (0.18 - 0.77) 245 -2.68 0.008 0.063  
 Using an alarm clock  if not using this aid 0.13 (0.02 - 0.81) 245 -2.20 0.029 0.117  
 Putting the medication eye-catchingly to different places if not using this aid 0.48 (0.23 - 1.00) 245 -1.98 0.049 0.131  
 Using additional aids not specified in the questionnaire if using additional aids 3.19 (1.06 - 9.62) 245  2.07 0.040 0.126  
 Symptom occurrence: having spots on the face / back if spots occur 1.62 (1.12 - 2.36) 240  2.56 0.011 0.073  
 Symptom distress: having spots on the face / back if spots give distress 1.69 (1.22 - 2.34) 151  3.17 0.002 0.024 * 
 Symptom occurrence: impotence (men only)  if impotent 0.72 (0.53 - 0.97) 129 -2.14 0.034 0.124  
 Symptom occurrence: having swollen ankles  if less swollen ankles 0.64 (0.45 - 0.91) 238 -2.53 0.012 0.075  
 Symptom occurrence: having trembling hands  if trembling hands 1.53 (1.05 - 2.23) 239  2.21 0.028 0.117  
 Symptom distress: having increased hair growth  if less distress about hair 0.70 (0.51 - 0.96) 140 -2.25 0.026 0.117  
 Symptom occurrence: having warts  if having warts 1.38 (1.00 - 1.90) 236  1.98 0.049 0.131  
 Symptom distress: having warts  if warts give distress 1.52 (1.02 - 2.27) 101  2.08 0.040 0.126  
 Symptom occurrence: having diarrhea if having diarrhea 1.59 (1.01 - 2.50) 239  2.03 0.044 0.126  
 Symptom distress: pain when passing water if passing water hurts 3.14 (1.06 - 9.31) 35  2.14 0.040 0.126  
 Weekday at the end of the week 1.04 (1.01 - 1.07) 244  3.15 0.002 0.024 * 
System  Center 1 vs center 2   0.51 (0.27 - 0.96) 246 -2.11 0.036 0.126  
related Center 1 vs other centers  0.23 (0.06 - 0.96) 246 -2.02 0.044 0.126  
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All of these variables were put into the multiple regression model, except for ‘symptom 
distress with having spots’, which we replaced by the occurrence dimension. The 
occurrence variable had far fewer missing values, yet behaved similarly to the distress 
variable in the simple regression model. Moreover, both variables highly correlated with 
each other (r=0.49). Table 4 presents the result of the multiple regression model. 
Significant associations existed between EM-measured non-adherence and gender 
(OR=0.46; CI=0.26-0.81), weekday (OR=1.04; CI=1.02-1.07), using a pillbox 
(OR=0.31; CI=0.16-0.61), and self-reported non-adherence (OR=3.08; CI=1.69-5.61). 
Table 4: Results of the multiple mixed logistic regression analysis  
Random effect Estimate df t p  
 Variance 1.898 234 15.06 <.0001  
      
Fixed effects OR (95% CI) df t p  
 Intercept 0.89 (0.01-70.5) 234 -0.05 0.95  
 Age 0.99 (0.97-1.02) 234 -0.55 0.58  
 Gender 0.46 (0.26-0.81) 234 -2.67 0.008 * 
 Weekday 1.04 (1.02-1.07) 234  3.20 0.001 * 
 Self-reported non-adherence 3.08 (1.69-5.61) 234  3.71 0.0002 * 
 Busyness 1.41 (0.82-2.44) 234  1.25 0.21  
 Self-efficacy 0.49 (0.22-1.07) 234 -1.80 0.07  
 Using a pillbox 0.31 (0.16-0.61) 234 -3.40 0.0007 * 
 Graft type:  Cadaveric vs living-related  1.78 (0.90-3.51) 234  1.67 0.09  
  Cadaveric vs living-unrelated  1.46 (0.61-3.53) 234  0.85 0.39  
 Having spots on the face / back 1.20 (0.84-1.69) 234  1.01 0.31  
A weak collinearity existed between some of the included variables. The non-
significance of self-efficacy is probably the consequence of a weak correlation with self-
reported non-adherence (r=0.22). Removing self-reported non-adherence from the 
model resulted in a lower p-value for self-efficacy (p=0.01). Other correlating predictor 
variables were busyness and age (r=-0.35). Alternately removing them from the model 
did not change the model’s final conclusion. A third predictor variable showing 
correlation with other predictors in the model was graft type. Persons who received a 
graft from a living-related person were younger (z=-7.2; p<0.0001), busier (z=4.1; 
p<0.0001), less self-efficacious (z=-2.9; p=0.003) and reported more non-adherence 
(z=2.1; p=0.03) than those who received a cadaveric graft. Because none of these 
factors seemed to entirely explain the association of living-related transplantation on 
non-adherence, we looked in the literature for additional information on expected 
differences between living (related) and cadaveric transplantation 14 18 32, and identified 
two additional explanatory variables. Recipients of a live donor graft might have a 
higher chance on pre-emptive transplantation 14, and have a stronger belief in the 
histocompatibility of the living-related graft 18. Our sample indeed showed strong 
differences in pre-emptive transplantation frequencies between living-related and 
cadaveric grafts: only 1% of the cadaveric graft transplantations were pre-emptive, 
compared to 20% of the living related (χ²=53.8; p<0.0001). Also living-related graft 
recipients had a stronger belief that “kidneys from living donors do not need as much 
immunosuppression as cadaver kidneys” (z=3.38; p=0.0007). Including both variables 
into the multiple model, however, did not change the results of table 4. 
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4.4. Discussion 
This study investigated period prevalence and risk factors of non-adherence to the 
immunosuppressive therapy in adult kidney transplant patients more than one year 
after transplantation, containing the largest sample ever of electronically monitored 
solid transplant recipients. Non-adherence in this sample was slightly lower compared 
to previous EM studies performed in the U.S. (see above) 3-5. Several explanations for 
this difference may be posited, for instance, adherent patients may have been more 
inclined to participate in the EM part of the study. Such a selection bias, however, was 
very unlikely, as we checked but did not find differences in non-adherence as 
measured by self-reported, health care provider report and blood assay between 
subjects participating and those not participating with EM 52. A second possible 
explanation for the observed prevalence differences between our study and published 
ones could be the protocols used to clean the data. We excluded subjects showing 
major non-adherence to the EM guidelines, which could have led to higher adherence 
estimates, as it is known that not excluding patients non-adherent to the EM guidelines 
leads to overestimating non-adherence 52. Again, this explanation is not likely to fully 
explain the observed differences. The reason is that two of our own studies in Belgian 
heart 53 and Dutch liver transplant patients 54 used a similar data cleaning protocol, but 
nevertheless found lower taking 53 and dosing 54 adherence prevalences than this study 
(a median 99% on both parameters). A third possible source of non-adherence 
prevalence variation can be found in regional differences among the compared studied 
samples. This geographical hypothesis is supported by a recent meta-analysis on 
individual patient data 55 that pooled self-reported non-adherence data of North 
American 18 and European patients 37 49, and by non-adherence research in non-
transplant populations 56 57. All these studies reveal a similar geographical pattern as 
can be observed in the just mentioned EM measurements in transplant patients: the 
highest non-adherence is found in the U.S., the lowest in European samples. Future 
research will have to confirm this preliminary evidence of regional variation and 
determine underlying dynamics. Causes are likely to be of health care system-related 
origin. Unfortunately, this study was not designed to study correlations between 
macro-level differences in health care systems (such as access and reimbursement 
policies) and individual medication adherence behavior. The only evidence our study 
offers about system-related factors is that differences were found between the two 
included centers. Although not significant after correction for multiple testing, our 
finding is supported by other research 5 35, and may indicate that characteristics of 
health care programs (like chronic disease/behavioral management practices) influence 
patients’ adherence.  
Aside from the health care system-related domain, this study identified a relatively 
small number of risk factors for non-adherence out of a large supply of candidate risk 
factors. The probability that these are not just statistical artifacts, but real risk factors 
of non-adherence, is very high. Moreover, some findings are very valuable for clinical 
practice, in that they offer both possibilities for identifying patients at risk for non-
adherence, as well as for enhancing adherence. An example of a clinically useful result 
is the detected link between self-efficacy and adherence, confirming earlier research in 
transplant 23 53, and other populations (e.g. HIV) 58 59. Efficacy cognitions can be 
influenced by clinical intervention (e.g. by inducing mastery experience) 60, and are 
therefore useful as a cornerstone concept in adherence enhancing programs. Other 
results with possible relevance for adherence remediation are the detected strong 
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associations between adherence and the use of medication aids, confirming research 
on medication aids done in HIV or glaucoma patients 61-65. Evidence for causal effects 
of medication aids on non-adherence exist for electronic 63-65 as well as non-electronic 
reminder devices (e.g. pillboxes) 66.  
Not useful for adherence remediation, but certainly helpful for detecting patients at risk 
for non-adherence, is the finding that a one-unit increase in self-reported non-
adherence resulted in a threefold higher odds on non-adherence as measured by EM. 
Self-reported non-adherence was the most powerful predictor in our multiple model, in 
spite of the fact that it is not regarded as a very sensitive method for measuring non-
adherence 36 67. Supported by earlier research 53, this finding demonstrates the 
usefulness of self-report for the detection of patients at risk for non-adherence. If done 
in a non-accusatory and non-threatening way, self-report can be an easy screening 
method for detecting patients with non-adherence problems, and can be integrated as 
a clinical parameter in the clinical follow-up of transplanted patients. 
The two last significant variables in the multiple model, weekday and gender, are not 
manipulatable. The gradual increase of non-adherence during the work week, 
culminating in the weekend, equals results of earlier research reporting a 
discontinuously higher non-adherence on weekend days 68. The variable gender on the 
other hand was not really expected to appear as a risk factor in this study. Of twelve 
kidney transplant studies that previously looked for gender differences 6 15-18 20-23 32 69 70, 
only one found that women were more non-adherent than men 21, the opposite result 
as ours. 
All remaining variables of the multiple model seemed to be explained by other included 
variables. Non-adherence of living-related graft recipients for instance, is higher 
because these patients score higher on risk factors such as age, busyness, self-
efficacy, health beliefs, and the lack of experience with dialysis 14 18. This list is 
probably not comprehensive, as estimates and inferences of the model including all 
these variables hardly differed from the one in Table 4. Therefore, further exploration 
of characteristics that increase non-adherence in living-related graft recipients is 
indicated. 
The results for many variables in this study were not conclusive. Among the risk factors 
that did not prove to be significant after correction for multiple testing, a substantial 
proportion will be statistical noise, though that proportion could be somewhat smaller 
than the corrected inferences suggested. Moderate correlations among many of the 
risk factors may have made our multiple testing correction slightly conservative 51. 
Hence, the evidence for variables such as ‘alcohol use’, or the health belief that 
‘immunosuppression is needed to keep the kidney’ is stronger than suggested in table 
3, especially because these particular variables have previously already been 
associated to non-adherence 14 18 29. Variables on the other hand for which evidence is 
weaker are the many symptom experience items. Contra-intuitively to the theoretical 
framework 28, symptoms that appeared in the simple modeling results were not the 
most frequently occurring or the most distressing symptoms 49 71. Because earlier 
studies did not do item specific analysis, we cannot compare our results to earlier 
findings. It would therefore be worthwhile to try to replicate these results on older 
symptom data using the same data analysis techniques we used for this study 53.  
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To conclude, we tested an extensive number of potential risk factors of non-adherence 
with immunosuppressive medication in adult kidney transplant patients on a stable 
medication regimen, and found a number of variables useful in detecting non-
adherence or enhancing adherence. Higher self-efficacy, pill box use, being female, 
and being in the beginning of the work week were unequivocally associated with 
higher adherence. Also, self-reported non-adherence proved to be useful in tracing 
non-adherence problems. Given the high adherence in our sample, the results of this 
study are especially relevant for similar drug-disease combinations, like heart 
transplant or HIV treatments. 
Reference list 
1. Denhaerynck K, Dobbels F, Cleemput I, Desmyttere A, Schafer-Keller P, Schaub S, et al. 
Prevalence, consequences, and determinants of nonadherence in adult renal transplant 
patients: a literature review. Transpl Int 2005;18(10):1121-33. 
2. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with 
medication regimens. Drugs 1995;49(3):321-7. 
3. Nevins TE, Kruse L, Skeans MA, Thomas W. The natural history of azathioprine compliance 
after renal transplantation. Kidney Int 2001;60(4):1565-70. 
4. Feldman HI, Hackett M, Bilker W, Strom BL. Potential utility of electronic drug compliance 
monitoring in measures of adverse outcomes associated with immunosuppressive agents. 
Pharmacoepidemiol Drug Saf 1999;8(1):1-14. 
5. Weng FL, Israni AK, Joffe MM, Hoy T, Gaughan CA, Newman M, et al. Race and 
electronically measured adherence to immunosuppressive medications after deceased donor 
renal transplantation. J Am Soc Nephrol 2005;16(6):1839-48. 
6. Vlaminck H, Maes B, Evers G, Verbeke G, Lerut E, Van Damme B, et al. Prospective study 
on late consequences of subclinical non-compliance with immunosuppressive therapy in 
renal transplant patients. Am J Transplant 2004;4(9):1509-13. 
7. Hilbrands LB, Hoitsma AJ, Koene RA. Medication compliance after renal transplantation. 
Transplantation 1995;60(9):914-20. 
8. Dobbels F, De Geest S, van Cleemput J, Droogne W, Vanhaecke J. Effect of late medication 
non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung 
Transplant 2004;23(11):1245-51. 
9. Cleemput I, Kesteloot K, Vanrenterghem Y, De Geest S. The economic implications of non-
adherence after renal transplantation. Pharmacoeconomics 2004;22(18):1217-34. 
10. Rosenberger J, Geckova AM, van Dijk JP, Nagyova I, Roland R, van den Heuvel WJ, et al. 
Prevalence and characteristics of noncompliant behaviour and its risk factors in kidney 
transplant recipients. Transpl Int 2005;18(9):1072-8. 
11. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made 
significant progress or is it time to rethink our analytic and therapeutic strategies? Am J 
Transplant 2004;4(8):1289-95. 
12. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft 
survival despite a marked decrease in acute rejection rates over the most recent era. Am J 
Transplant 2004;4(3):378-83. 
13. Sabaté E. Adherence to long-term therapies: Evidence for action. Geneva: World Health 
Organisation; 2003. 
14. Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for 
non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional 
study. Nephrol Dial Transplant 2004;19(12):3144-9. 
15. Ghods AJ, Nasrollahzadeh D, Argani H. Risk factors for noncompliance to 
immunosuppressive medications in renal transplant recipients. Transplant Proc 
2003;35(7):2609-11. 
16. Raiz LR, Kilty KM, Henry ML, Ferguson RM. Medication compliance following renal 
transplantation. Transplantation 1999;68(1):51-5. 
Prevalence and risk factors of non-adherence  
 
73 
 
17. Papajcik D, Mastroianni B, Goormastic M, Flechner SM. A tool to identify risk factors for 
noncompliance in the adult renal transplant recipient. Transplant Proc 1999;31(4A):84S-
86S. 
18. Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal 
transplant: a multicenter study. Transplantation 1998;66(12):1718-26. 
19. Siegal B, Greenstein SM. Differences between compliers and partial compliers: a multicenter 
study. Transplant Proc 1998;30(4):1310-1. 
20. Sketris I, Waite N, Grobler K, West M, Gerus S. Factors affecting compliance with 
cyclosporine in adult renal transplant patients. Transplant Proc 1994;26(5):2538-41. 
21. Frazier PA, Davis-Ali SH, Dahl KE. Correlates of noncompliance among renal transplant 
recipients. Clin Transplant 1994;8(6):550-7. 
22. Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D, Schweizer R. Noncompliance in organ 
transplant recipients. Transplant Proc 1989;21(1 Pt 1):833-4. 
23. De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, et al. Incidence, 
determinants, and consequences of subclinical noncompliance with immunosuppressive 
therapy in renal transplant recipients. Transplantation 1995;59(3):340-7. 
24. Teixeira de Barros C, Cabrita J. Noncompliance with immunosuppressive therapy: 
prevalence and determinants. Transplant Proc 2000;32(8):2633. 
25. Cherubini P, Rumiati R, Bigoni M, Tursi V, Livi U. Long-term decrease in subjective 
perceived efficacy of immunosuppressive treatment after heart transplantation. J Heart 
Lung Transplant 2003;22(12):1376-80. 
26. Bandura A. Self-efficacy: The exercise of control. New York: W.H. Freeman; 1997. 
27. Reyna L. The Debate Continues Cognition, Behavior and Causality: A Broad Exchange of 
Views Stemming from the Debate on the Causal Efficacy of Human Thought: Introduction. 
Journal of Behavior Therapy and Experimental Psychiatry 1996;27(4):321. 
28. Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: Using common sense to 
understand treatment adherence and affect cognition interactions. Cognit Ther Res 
1992;16(2):143-163. 
29. Yavuz A, Tuncer M, Gurkan A, Demirbas A, Suleymanlar G, Ersoy F, et al. Cigarette smoking 
in renal transplant recipients. Transplant Proc 2004;36(1):108-10. 
30. Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication 
adherence in HIV-positive drug users. AIDS Patient Care STDS 2004;18(7):385-93. 
31. Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D, et al. Medication 
adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc 1999;47(2):172-
83. 
32. Yavuz A, Tuncer M, Erdogan O, Gurkan A, Cetinkaya R, Akbas SH, et al. Is there any effect 
of compliance on clinical parameters of renal transplant recipients? Transplant Proc 
2004;36(1):120-1. 
33. Wagner GJ. Does discontinuing the use of pill boxes to facilitate electronic monitoring 
impede adherence? Int J STD AIDS 2003;14(1):64-5. 
34. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal 
allografts. Overriding effects of HLA matching and socioeconomic factors. N Engl J Med 
1992;327(12):840-5. 
35. Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, et al. Correlates of 
Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients The Swiss 
HIV Cohort Study. Epidemiology and social science In press. 
36. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of 
multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 
2001;134(10):968-77. 
37. De Geest S, Denhaerynck K, Schäfer-Keller P, Bock A, Steiger J. Supporting Medication 
Adherence in Renal Transplantation - the SMART study. Swiss Medical Weekly In press. 
38. Fierz K, Steiger J, Denhaerynck K, Bock A, De Geest S. Prevalence, severity and correlates 
of alcohol use in renal transplant patients. Clinical transplantation In press. 
39. Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. 
Control Clin Trials 1997;18(3):187-203. 
Prevalence and risk factors of non-adherence  
 
74 
 
40. Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires 
subtle interpretation. Clin Pharmacol Ther 2000;67(1):44-7. 
41. Deschamps AE, Graeve VD, van Wijngaerden E, De Saar V, Vandamme AM, Van 
Vaerenbergh K, et al. Prevalence and correlates of nonadherence to antiretroviral therapy in 
a population of HIV patients using Medication Event Monitoring System. AIDS Patient Care 
STDS 2004;18(11):644-57. 
42. De Geest S, Abraham I, Gemoets H, Evers G. Development of the long-term medication 
behaviour self-efficacy scale: qualitative study for item development. J Adv Nurs 
1994;19(2):233-8. 
43. Martin M, Park DC. The Martin and Park Environmental Demands (MPED) Questionnaire: 
psychometric properties of a brief instrument to measure self-reported environmental 
demands. Aging Clin Exp Res 2003;15(1):77-82. 
44. Schreurs PJ, Tellegen B, Willige GV. Gezondheid, stress en coping: de ontwikkeling van de 
Utrechtse coping-lijst [Health, stress and coping: The development of the Utrechtse Coping 
Scale]. Gedrag:-Tijdschrift-voor-Psychologie 1984;12(1-2):101-117. 
45. Denhaerynck K, Abraham I, Gourley G, Drent G, De Vleeschouwer P, Papajcik D, et al. 
Validity testing of the Long-Term Medication Behavior Self-Efficacy Scale. J Nurs Meas 
2003;11(3):267-82. 
46. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring 
depression. Archives of General Psychiatry 1961;4:561-571. 
47. Hole RW, Rush AJ, Beck AT. A cognitive investigation of schizophrenic delusions. Psychiatry: 
Journal for the Study of Interpersonal Processes 1979;42(4):312-319. 
48. Moons P, De Geest S, Versteven K, Abraham I, Vlaminck H, Moens G, et al. Psychometric 
properties of the "Modified Transplant Symptom Occurrence and Symptom Distress Scale". 
J Nurs Meas 2001;9(2):115-34. 
49. Moons P, Vanrenterghem Y, Van Hooff JP, Squifflet JP, Margodt D, Mullens M, et al. Health-
related quality of life and symptom experience in tacrolimus-based regimens after renal 
transplantation: a multicentre study. Transpl Int 2003;16(9):653-64. 
50. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern 
Med 1990;150(7):1509-10. 
51. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U 
S A 2003;100(16):9440-5. 
52. Denhaerynck K, Schäfer-Keller P, Young J, Steiger J, Bock A, Köfer S, et al. Challenging 
electronic medication monitoring as gold standard: a test of its assumptions. Nursing 
research In press. 
53. De Geest S, Abraham I, Moons P, Vandeputte M, Van Cleemput J, Evers G, et al. Late acute 
rejection and subclinical noncompliance with cyclosporine therapy in heart transplant 
recipients. J Heart Lung Transplant 1998;17(9):854-63. 
54. Drent G, Haagsma EB, Geest SD, van den Berg AP, Ten Vergert EM, van den Bosch HJ, et 
al. Prevalence of prednisolone (non)compliance in adult liver transplant recipients. Transpl 
Int 2005;18(8):960-6. 
55. Denhaerynck K, Desmyttere A, Dobbels F, Moons P, Young J, Siegal B, et al. Prevalence of 
noncompliance with the immnosuppressive regimen in North American and European renal 
transplant recipients. Progress in Transplantation In press. 
56. Cerveri I, Locatelli F, Zoia MC, Corsico A, Accordini S, de Marco R. International variations in 
asthma treatment compliance: the results of the European Community Respiratory Health 
Survey (ECRHS). Eur Respir J 1999;14(2):288-94. 
57. Bleyer AJ, Hylander B, Sudo H, Nomoto Y, de la Torre E, Chen RA, et al. An international 
study of patient compliance with hemodialysis. Jama 1999;281(13):1211-3. 
58. Wilson KJ, Doxanakis A, Fairley CK. Predictors for non-adherence to antiretroviral therapy. 
Sex Health 2004;1(4):251-7. 
59. Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of HAART 
discontinuation among injection drug users. AIDS Care 2005;17(5):539-49. 
60. Bandura A. Toward a Unifying Theory of Behavioral Change. Psychological Review 
1977;84:191-215. 
Prevalence and risk factors of non-adherence  
 
75 
 
61. Kalichman SC, Cain D, Cherry C, Kalichman M, Pope H. Pillboxes and antiretroviral 
adherence: prevalence of use, perceived benefits, and implications for electronic medication 
monitoring devices. AIDS Patient Care STDS 2005;19(12):833-9. 
62. Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, et al. A prospective study of 
predictors of adherence to combination antiretroviral medication. J Gen Intern Med 
2002;17(10):756-65. 
63. Chang JS, Jr., Lee DA, Petursson G, Spaeth G, Zimmerman TJ, Hoskins HD, et al. The effect 
of a glaucoma medication reminder cap on patient compliance and intraocular pressure. J 
Ocul Pharmacol 1991;7(2):117-24. 
64. Laster SF, Martin JL, Fleming JB. The effect of a medication alarm device on patient 
compliance with topical pilocarpine. J Am Optom Assoc 1996;67(11):654-8. 
65. Sclar DA, Skaer TL, Chin A, Okamoto MP, Nakahiro RK, Gill MA. Effectiveness of the C Cap 
in promoting prescription refill compliance among patients with glaucoma. Clin Ther 
1991;13(3):396-400. 
66. Heneghan CJ, Glasziou P, Perera R. Reminder packaging for improving adherence to self-
administered long-term medications. Cochrane Database Syst Rev 2006(1):CD005025. 
67. Schäfer-Keller P, Steiger J, Denhaerynck K, Bock A, De Geest S. Using electronic monitoring 
as reference standard: how well do state of measurement methods measure medication 
adherence in kidney transplant recipients. American Journal of Transplantation 
2005;5(Suppl. 11):S331. 
68. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical 
therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used 
methods of measuring adherence to topical therapy overestimate actual use. J Am Acad 
Dermatol 2004;51(2):212-6. 
69. Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug 
regimens after renal transplantation: comparison of self-report and clinician rating with 
electronic monitoring. Transplantation 2004;77(5):786-9. 
70. Vasquez EM, Tanzi M, Benedetti E, Pollak R. Medication noncompliance after kidney 
transplantation. Am J Health Syst Pharm 2003;60(3):266-9. 
71. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Conversion 
from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and 
cardiovascular risk profile. Am J Transplant 2004;4(6):937-45. 
  
Non-adherence differences between countries  
 
77 
  
5. NON-ADHERENCE WITH IMMUNOSUPPRESSIVE DRUGS IS 
HIGHER IN NORTH AMERICAN COMPARED TO EUROPEAN 
RENAL TRANSPLANT PATIENTS 
Kris Denhaerynck, Ariane Desmyttere, Fabienne Dobbels, Philip Moons, Jim Young, 
Bonita Siegal, Stuart Greenstein, Jürg Steiger, Yves Vanrenterghem, Jean-Paul 
Squifflet, Johannes P. Van Hooff, Sabina De Geest 
 
In press: Progress in Transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-adherence differences between countries  
 
78 
  
5.1. Introduction 
Non-adherence with immunosuppressive medication negatively impacts clinical and 
economical outcomes in renal transplantation and has therefore become under 
increased scrutiny 1-14. A recent comprehensive review from our group on non-
adherence in renal transplantation 12 reports that the prevalence of non-adherence 
with immunosuppressive drugs ranges from 2% to 67% depending on the case finding 
methods, measurement methods, and operational definitions used. The weighted mean 
of non-adherence with immunosuppressive drugs over different publications is 27.7%. 
Non-adherence is an etiological factor in 16.3% of the graft losses and 19.9% of the 
late acute rejections in renal transplant recipients 12. 
Studying underlying dynamics and factors linked to non-adherence with 
immunosuppressive drugs in renal transplantation provides important information to 
develop strategies to identify patients at risk and develop adherence enhancing 
interventions. Correlates, determinants or risk factors for non-adherence can be 
categorized using the recently published WHO taxonomy. This taxonomy consists of 5 
groups of factors: (1) socio-demographic factors, (2) patient related factors, (3) 
condition related factors, (4) treatment related factors and (5) health care team and 
health care system related factors 11. The relationship between the 4 first categories 
and non-adherence with the immunosuppressive regimen has been explored to some 
extent in transplant populations 12 13 15. Yet, the last category of health care team and 
health care system related factors has received limited attention so far. 
System factors can be explored at the micro, meso and macro level. The micro level 
refers to patient-provider interaction such as for instance the quality of the patient 
provider relationship and communication style. The relationship between the health 
care provider and the patient is an overlooked variable when trying to understand non-
adherence in transplant populations. To our knowledge, only Wolff et al. 16 identified 
barriers for effective patient provider interaction in view of adherence in a qualitative 
study focusing on pediatric transplant recipients. More specifically, they identified 
following risk factors for non-adherence: insufficient information regarding health and 
treatment (40%); no communication about non-adherence (34%); health care 
providers have given up and rendered the responsibility for non-adherence to the 
patient (34%); loss of trust in doctors (33%); feeling of not being taken seriously 
(24%); patients do not want to bother health care providers or health care providers 
do not want to be called in case of questions (21%); and loss of praise for adherence 
achievements (20%)16. 
System factors at the meso level relate to characteristics of the transplant center. A 
center-specific effect in view of clinical outcome was observed among European heart 
transplant centers17, although this finding has not been confirmed in lung transplant 
centers18. Weng et al19 observed a center effect in view of prevalence of non-
adherence with immunosuppressive drugs among renal transplant centers participating 
in a multi-site study. Non-adherence was assessed by electronic monitoring, and 
analyses were controlled for other potential influencing factors. Yet, these authors did 
not explore potential underlying dynamics explaining this center effect, such as for 
instance the provision of continuity of care, the skill mix of teams, time pressures and 
time constraints of overworked health care providers and support of health care 
providers to patients in view of self management and behavioral support 11 20. There 
are indeed some indications in the transplant literature showing that lack of continuity 
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of care and decreased supervision were positively related with higher non-adherence. 
More specifically, distance from the transplant center 21-24 and not being under direct 
supervision of the transplant team 25 26 were found to be positively correlated with non-
adherence. Wolff et al. 16 also found that lack of time of health care provider was 
perceived as a risk factor for non-adherence in pediatric renal transplant patients. 
Variability of prevalence rates in view of non-adherence with the immunosuppressive 
regimen among health care systems suggests that factors at the macro level might 
also be associated with non-adherence. More specifically, prevalences of non-
adherence with immunosuppressive therapy in studies including European patients 
range from 13% to 36% 3 4, and studies including US patients range from 2% to 55% 1 
9 21 27-33, respectively. These data suggest a somewhat higher level of non-adherence in 
US patients. However, the wide variety in methodologies used prevents firm 
conclusions. Further research is needed to substantiate if being a patient in the US is 
indeed associated with a higher probability of being non-adherent compared to being a 
patient in Europe. 
The purpose of this study was therefore twofold: 1) to assess if there exists a 
difference in the prevalence of self-reported non-adherence with immunosuppressive 
regimen between European and North American kidney transplant recipients, and 2) to 
explore differences in prevalence of non-adherence among recipients of different 
European countries. This study thus focuses on the macro level of system factors by 
exploring possible variation among different health care systems. 
5.2. Methodology 
5.2.1. Design and sample 
This descriptive comparative study pooled data from 3 independently performed, yet 
methodologically similar cross-sectional, descriptive, multi-center studies conducted in 
North America 32 34 and Western Europe (Belgium / The Netherlands and Switzerland) 
35 36, respectively. Data collection for the North-American study was performed 
between June 1995 and December 1995, in 56 U.S. renal transplant centers 32. 
Patients were 18 years or older, taking cyclosporine, and having a functioning renal 
graft. Of the 3000 renal transplant recipients approached, 1563 (52.1%) returned valid 
questionnaires. 
Data collection for the Belgian / Dutch study took place during the period December 
1999 to December 2000, in three renal transplant centers: two in Belgium (the 
University Hospitals of Leuven and the University Hospital St-Luc in Brussels) and one 
in the Netherlands (the Academic Hospital of Maastricht). This study was part of a 
wider investigation on quality of life of renal transplant recipients 35. Patients in this 
study were all 18 years or older, Dutch- or French-speaking, literate, at least 6 months 
post-transplant, taking immunosuppressive drugs including tacrolimus for at least 6 
months, and being followed-up at one of the participating transplant centers. Exclusion 
criteria were re-transplantation and multiple organ transplantation. Of the 350 patients 
approached, 272 (77.7%) returned valid questionnaires. 
Data collection for the Swiss study (SMART) took place from June 2001 to December 
2004 in the Kantonsspital Aarau and the University Hospital Basel 36. This study 
assessed subclinical non-adherence with the immunosuppressive regimen in adult renal 
transplant recipients who were at least 1 year post-transplantation, 18 years or older, 
literate, French- or German-speaking, and receiving post-transplant follow-up at one of 
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the participating centers. Exclusion criteria were patients being unable to read the 
questionnaires when using glasses, lack of mental clarity and not being able to manage 
the medication independently. Of the 413 eligible patients, 342 (82.8%) patients gave 
informed consent and returned valid questionnaires. 
5.2.2. Variables and measurement methods 
All three studies used similar methodology to assess non-adherence with the 
immunosuppressive regimen 32. Non-adherence was assessed by self-report using one 
item from the Siegal scale 37 assessing the taking dimension of medication taking. 
Patients scored how often in the past four weeks they had not taken their 
immunosuppressive drugs on a 5-point Likert scale ranging from 'never forgotten' 
(score 0) to 'forgotten every day' (score 5). Because the distribution of answer patterns 
was skewed, answers were dichotomized. Patients reporting ‘never forgotten’ their 
immunosuppressive drugs during the last 4 weeks (score 0) were considered to be 
adherent similar to the scoring of the original Siegal scale37. Patients were considered 
to be non-adherent if they forgot their immunosuppressive medication at least once 
during the past four weeks (score 1-5) 32. This admittedly stringent definition of non-
adherence was based on the well known underreporting of non-adherence associated 
with self-report 38. Moreover, evidence from the renal and the heart transplant 
population shows that already minor deviations from dosing schedule are associated 
with an increased risk for poor clinical outcome 9 39, substantiating the choice of this 
stringent cut-off. 
No validity, reliability or diagnostic value of the Siegal scale has been reported by the 
researchers who developed the instrument. Our research group assessed the 
diagnostic value of the 4 item Siegal scale in the Swiss adherence study in renal 
transplantation36 using electronic monitoring as gold standard 40. Non-adherence as 
assessed with the 4–item Siegal scale was defined as any deviation from perfect 
adherence on 1 of the 4 items. Diagnostic values were following: sensitivity: 25.7%; 
specificity 89.6%; Likelihood ratio of a positive test result: 2.5 and area under the 
curve was 0.576 40. These results show the well known characteristics of self-report 
measures of non-adherence in that they underreport non-adherence 41. 
In addition to non-adherence, selected demographic (i.e. gender, age and level of 
education) and clinical variables (i.e. number of transplants received, type of donor, 
months post-transplantation, and presence of diabetes mellitus), were also recorded. 
The operational definition of educational level needed to be standardized between 
European and U.S. patients. This was done by categorizing patients as those with ‘very 
low educational level' referring to a less-than-high school educational level; 'low 
educational level' meaning a high school education; and 'medium / high educational 
level' referring to a post-high school or professional degree 40. Since the sample 
included patients speaking French, Dutch and German, the original English 
questionnaire was translated in these respective languages using the adapted Brislin 
protocol 41. 
5.2.3. Data collection 
In all three studies, patients were approached by a member of the research team 
either during an outpatient clinic follow-up appointment or by phone. The 
questionnaires were filled out by the patient at home and sent back in pre-stamped 
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and pre-addressed envelopes. All three studies had been approved by the respective 
local ethics committees. 
5.2.4. Data analysis 
Demographic and clinical characteristics, and prevalence of non-adherence were 
summarized for the respective samples using appropriate descriptive measures based 
on the measurement level and the distribution of the respective variables. Univariable 
analyses used to compare renal transplant recipients regarding the demographic and 
clinical factors and non-adherence were chi-square test and student t-test as 
appropriate. These analyses were performed using the statistical program SPSS, 
version 9.0 for Windows. Level of significance was set at 0.05. 
In order to discuss the independent effect of continent on prevalence of non-
adherence, multivariable analysis was performed using logistic regression with a single 
random effect. For this analysis, patients within each center were assumed to be 
correlated, whereas data from patients from different centers were assumed to be 
independent observations. To model the probability of patient non-adherence, ‘mixed’ 
models were used with center as a random effect and all other predictors as fixed 
effects. These models were fit using the NLMIXED procedure in SAS version 8.1 (SAS 
Institute Inc., Cary, NC), with optimization by a conjugate gradient method. A multiple 
logistic regression fit without center as an effect was used to provide suitable starting 
values for optimizing the mixed model with center as a random effect. 
5.3. Results 
5.3.1. Demographic and clinical characteristics in European 
and U.S. samples 
European and American patients differed on most demographic and some clinical 
characteristics (table 1). More specifically, the U.S. sample was younger, had a higher 
percentage of females, was better educated, and comprised a higher proportion of 
patients with more than one transplant than the European sample (table 1). 
Furthermore, U.S. patients had a shorter post-transplant status compared to European 
patients, and a higher proportion suffered from diabetes mellitus. The type of donor 
was similar for both U.S. and European patients. 
 
5.3.2. Non-adherence in European compared to U.S. 
patients 
In the European sample, 13.2% of respondents reported medication non-adherence in 
the last four weeks compared to 19.3% of U.S. respondents (p<0.001). Because 
differences between groups, the following demographic and clinical factors (table 1) 
were controlled for in multivariable analyses: gender, age, educational level, number of 
transplants received, type of donor, presence of diabetes mellitus, and time post-
transplantation. A mixed model using center as a random effect and all other factors as 
fixed effects showed higher non-adherence with immunosuppressive drugs in U.S 
patients compared to European patients (OR=1.78; 95%CI: 1.10-2.89; p=0.019) (table 
2). 
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Table 1: Demographic and clinical variables in the European versus the U.S. sample. 
 European 
sample 
(N=616) 
U.S. sample 
(N=1563) 
p-value 
Gender: 
 % Male 
 
60.5% 
 
48.8% 
 
<0.001 (∗) 
Age (in years): 
  Mean ± SD  
 
53.01 ± 12.92 
 
47.4 ± 12.8 
 
<0.001 (°) 
Educational level: 
 % Very low education   
 % Low education 
 % Medium/high education 
 
25.4% 
51.3% 
23.3% 
 
13.0% 
66.3% 
20.6% 
 
<0.001 (∗) 
Number of transplant 
 %1st renal transplant 
 % >1 renal transplant   
 
93.6% 
6.4% 
 
88.0% 
12.0% 
 
  0.002 (∗) 
Type of donor: 
 % Living donor 
 
26.2% 
 
24.2% 
 
  0.318 (∗) 
Diabetes mellitus: 
 % Diabetes 
 
15.3% 
 
29.4% 
 
<0.001 (∗) 
Time post-TX (months): 
  Mean ± SD 
 
64.20 ± 67.25 
 
36.2 ± 32.4 
 
<0.001 (°) 
Immunosuppressives 
 % Cyclosporine 
 % Tacrolimus 
 % Other 
 
37.1% 
54.7% 
 8.2% 
 
100.0% 
 
<0.001(▫) 
Non-adherence 
 % Non-adherent 
 
13.2% 
 
19.3% 
 
<0.001 (*) 
(∗) = chi-square, (°) = student t test, (▫) = Fisher exact test 
 
 
Table 2: Comparison of non-adherence in the European versus the U.S. sample: 
logistic regression: Adjusted Odd’s Ratios (95% Confidence Intervals). 
 AOR (95% CI) 
(*) 
 
Interpretation: 
Adherence is higher in 
patients who… 
p-value 
Gender  1.08 (0.84-1.38) - 0.5455 
Age   1.03 (1.02-1.04) Are older <.0001 
Educational level   0.86 (0.69-1.06) - 0.1568 
Number of transplant   0.93 (0.68-1.28) - 0.6586 
Type of donor  0.59 (0.45-0.79) Have cadaveric grafts 0.0006 
Diabetes mellitus  1.33 (0.98-1.80) Have diabetes mellitus 0.0648 
Time post-transplantation   0.99 (0.99-1.00) Are recently transplanted 0.0001 
Continent  1.78 (1.10-2.89) Are European 0.0190 
Random effects variance 1.13 (0.99-1.29) - 0.0685 
Intercept 1.20 (0.42-3.43) - 0.7340 
(*) AOR= Adjusted Odd’s Ratio, CI= Confidence Interval 
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5.3.3. Comparison of non-adherence among European renal 
transplant patients 
Comparison of clinical and demographic factors revealed that Belgian, Dutch and Swiss 
renal transplant patients differed in view of educational level, number of transplants 
received, percentage of living donor and time since transplantation (table 3). 
 
Table 3: Demographic and clinical variables in the European countries (Belgium, the 
Netherlands and Switzerland). 
 Belgium 
(n=187) 
The 
Netherlands 
(N=85) 
Switzerland 
(N= 342) 
p-value 
Gender: 
 % Male 
 
64.2% 
 
59.5% 
 
58.5% 
 
  0.435 (*) 
Age (in years): 
  Mean ± SD 
 
51.8 ± 12.4 
 
55.4 ± 12.8 
 
53.2 ±13.2 
 
  0.121 (°) 
Educational level: 
 % Very low education   
 % Low education 
 % Medium/high education 
 
29.9% 
52.4% 
17.6% 
 
64.6% 
25.3% 
10.1% 
 
14.0% 
57.0% 
28.9% 
 
<0.001 (*) 
Number of transplant 
 %1st renal transplant 
 % >1st renal transplant 
 
100.0% 
0.0% 
 
100.0% 
0.0% 
 
88.4% 
11.6% 
 
<0.001 (*) 
Type of donor: 
 % Living donor 
 
1.6% 
 
18.8% 
 
42.1% 
 
<0.001 (*) 
Diabetes mellitus: 
 % Diabetes 
 
15.0% 
 
20.0% 
 
14.3% 
 
  0.425 (*) 
Time post-TX (months): 
  Mean ± SD 
 
25.4 ±28.8 
 
29.8 ±26.7 
 
93.7 ±73.8 
 
<0.001(°) 
Non-adherence 
 % Non-adherent 
 
16.0% 
 
14.1% 
 
11.4% 
 
  0.314 (*) 
(∗) = chi-square, (°) = one way ANOVA 
 
Univariable analyses revealed no significant differences between non-adherence in the 
European countries: 16.0% in Belgium, 14.1% in the Netherlands and 11.4% in 
Switzerland respectively (chi-square, p=0.314). Given the differences in patient and 
clinical characteristics (table 3), additional logistic regression analyses compared the 
European countries in view of non-adherence (table 4), showing greater non-
adherence in Belgium as compared to the Netherlands (OR=0.27; 95%CI: 0.09-0.80; 
p=0.0186) and to Switzerland (OR=0.17; 95%CI: 0.07-0.42; p=0.0001), but no 
differences were seen between Dutch and Swiss patients (OR=0.61; 95%CI:0.20-1.92; 
p=0.4010) (table 4). 
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Table 4: Comparison of non-adherence in the European countries (Belgium, the 
Netherlands, Switzerland): logistic regression: Adjusted Odd’s Ratios (95% Confidence 
Intervals). 
  
AOR (95% CI) 
(*) 
Interpretation: 
Adherence is higher in 
patients who… 
p-
value 
Gender  1.40 (0.78-2.51) - 0.2558 
Age   1.00 (0.98-1.03) - 0.6947 
Educational level   1.09 (0.72-1.67) - 0.6783 
Number of transplant   1.70 (0.45-6.38) - 0.4309 
Type of donor  0.27 (0.12-0.61) Have cadaveric grafts 0.0017 
Diabetes mellitus  1.75 (0.66-4.61) - 0.2576 
Time post-transplantation   0.99 (0.99-1.00) Are recently transplanted <.0001 
Belgium versus 
the Netherlands 
0.27 (0.09-0.80) Are Dutch 0.0186 
Belgium versus Switzerland 0.17 (0.07-0.42) Are Swiss 0.0001 
The Netherlands versus 
Switzerland 
0.61 (0.20-1.92) - 0.4010 
(*) AOR= Adjusted Odd’s Ratio, CI= Confidence Interval 
 
5.4. Discussion 
To our knowledge, this is the first study that assessed if health care system related 
correlates at the macro level are associated with non-adherence with 
immunosuppressive drugs in transplantation. This study pooled findings from studies 
with similar methodology and showed that non-adherence is higher in North-American 
compared to European patients 1 9 21 27-33. Moreover, variability was observed in non-
adherence rates among European countries, with Belgium showing higher non-
adherence in multivariable analysis. 
Limited other empirical evidence of non-transplant populations confirms the higher 
prevalence of non-adherence in U.S. patients. Using structured interviews, Cerveri et 
al. 42 compared non-adherence between U.S., Dutch and Belgian patients, and found a 
significantly higher level of adherence in Belgian and Dutch patients compared to U.S. 
patients 42. A comparison of appointment non-adherence between U.S., Japanese and 
Swedish hemodialysis patients also found higher non-adherence rates in the U.S. 
population 43. Hecking et al. 44 compared non-adherence rates among European 
dialysis patients in France (20 units-672 pts), Germany (21-571), Italy (20-600), Spain 
(20-576), UK (20-620) in view of skipping or shortening behavior of dialysis sessions. 
Variability in non-adherence rates were found (skipping: France: 0.3%, Germany: 
0.9%, Italy: 8.8%, Spain: 6.6%, UK: 12.6%; shortening France: 7.3%, Germany: 
9.5%, Italy: 8.8%, Spain: 6.6%, UK: 12.6%). Unfortunately, this study did not include 
one of the countries we studied. 
The question that emerges when observing this variability in adherence rates among 
countries is which potential underlying dynamics at the macro level might explain this 
variability of non-adherence? It could be hypothesized that differences in health care 
system characteristics, such as for instance health insurance coverage and regulations 
on the reimbursement of (immunosuppressive) drugs or medical treatment, might be 
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important for the observed higher rate in non-adherence between the US and Europe. 
The importance of health insurance as a potential influencing factor in view of non-
adherence was already suggested by Butkus et al., showing that non-adherence was 
higher in black uninsured renal transplant patients in the US 33. European countries 
have compulsory health insurance with provides easier access and equity in care. 
Moreover, the reimbursement of immunosuppressive drugs, even long-term after 
transplantation, is more favorable, with some countries completely reimbursing 
immunosuppressive drugs (Belgium & the Netherlands) and other countries requiring a 
limited percentage of co-payments (Switzerland). This is quite different from the US 
health care system where financial problems have been identified as the most 
important factor in non-adherence in heart transplant recipients 45 46. Yet, an increasing 
number of patients in Europe also report that the financial burden becomes heavier as 
the medication regimen (other drugs) and follow-up after transplantation necessitates 
co-payments. In a study in Switzerland 19% of the patients reported that did not have 
enough finances to pay the medication (SMART study, unpublished findings 22). 
Explaining possible dynamics among European countries is more challenging given that 
the health care systems are more similar. One could speculate that trans-cultural 
factors, especially with regard to specific illness beliefs, might differ among patients 
from different countries. Previous work in the US and Switzerland showed the 
importance of these health beliefs as a correlate of non-adherence 32 36. 
Future research should try to further elucidate which system factors at micro, meso 
and macro level are important in explaining non-adherence with immunosuppressive 
drugs in transplant populations. Attention should also be given at unraveling the 
underlying dynamics. This information is crucial to develop and implement adherence 
enhancing interventions. More specifically, information concerning the relative 
importance of patient-provider relationship, overworked health care providers, weak 
capacity of system to educate and follow-up patients, and limited community support 
provides clue in this direction. A more pronounced focus on system factors in 
developing adherence enhancing interventions is also suggested by the chronic illness 
literature indicating that providing care within an acute care model to a chronic patient 
population results in poor outcomes and higher costs 11 47. It has been argued that 
system change towards a chronic care model that integrates medical, psychosocial and 
behavioral dimensions of transplant management, that guarantees continuity of care, 
that places a strong emphasis on patient’s active role and adequate self-management 
and that employs health care workers who have the necessary skills for behavioral 
management results in favorable patient outcomes 11 47. 
5.5. Limitations of the study 
Some limitations of this study merit discussion. From a methodological point of view, it 
needs to be mentioned that we pooled data of studies differencing in the timing of 
data collection, inclusion and exclusion criteria, and response rates. The fact that the 
Belgian / Dutch study included renal transplant patients with a minimum of 6 months 
after their first transplantation only, while the Swiss study included all renal transplant 
patients minimum 1 year post-transplant and the U.S. study included simply all 
transplant recipients with a functioning graft, explains both the difference in number of 
transplants received and the difference in time after transplantation. Differences in 
type of donor among countries confirm the known differences in living related donation 
in different countries 48. Yet, when controlling for these differences in multivariable 
analysis, the differences in non-adherence persisted. 
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We do not think that the different data collection points in the three pooled studies 
have influenced our findings. Adherence seems rather stable over time in the absence 
of intervention 11, and therefore we do not expect that the different data collection 
periods will have introduced a major bias into the current study. A different time of 
data collection will certainly involve differences in prescribed immunosuppressive 
medication. It is not expected that the use of different immunosuppressive medication 
had an influence on adherence levels in the respective studies. However, further 
research is needed to explore the relationship between adherence behavior and the 
type of immunosuppressive medication. Concerning differences in response rates, we 
could hypothesize that the lower response rate in the U.S. sample hides in fact even a 
higher prevalence of non-adherence, as non-adherent patients might have been 
unwilling to participate in the study. 
A further limitation of this study is that non-adherence was measured by self-report, 
which is known to underestimate non-adherence, because of memory bias and / or 
untruthful answer patterns 41,51. Self-report also does not allow the detection of 
patterns of medication taking behavior; this is in contrast to the more reliable 
electronic event monitoring 49. Observed differences in non-adherence could be due to 
differences in the willingness of U.S. and European patients to disclose non-adherence 
by self-report, yet, there is no empirical evidence available to support this hypothesis 
to date, neither in transplant nor in non-transplant patient populations. 
We used a single item of the 4 item Siegal scale as only this item was used in all three 
studies we pooled. This item assessed the most important dimension of medication 
taking behavior. Admittedly, we can not report specific validity data for this single item. 
As mentioned above we did preliminary validation work for the 4 item scale using 
electronic monitoring as gold standard as part of the Swiss renal transplant study40. 
Future work could focus on determinening the diagnostic value of the separate and 
combined items of the Siegal scale. It is perhaps important to mention our finding that 
a conglomerate measure of non-adherence with the immunosuppressive regimen 
combining information of self-report, collateral report of the clinicians and assay 
showed the best validity using electronic monitoring as gold standard 40. This finding is 
congruent with a recent review on adherence to medication 41. The feasibility of using 
such a conglomerate measure or even better using electronic monitoring is however 
limited in large scale adherence studies. In these large scale studies a trade off needs 
to be found between feasibility and accuracy of measurement. Our experience with 
adherence assessment as part of the Swiss HIV cohort study might be illustrative in 
this regard 52. We assessed non-adherence using two self report items in 3607 
patients. One item assessed the taking dimension of medication taking, the second the 
presence of drug holidays. Definition of non-adherence was similar to our transplant 
study, i.e. at least 1 dose missed in the past 4 weeks. We could establish validity based 
on a strong correlation between the taking adherence item and the proportion of 
patients virally suppressed in the past 6 months 52. 
A next limitation of our study is the lack of variation of our sample with regard to the 
number of included centers in Europe, the used immunosuppressive regimens (due to 
inclusion criteria in the US, Belgian and Dutch studies), and the inclusion of patients 
from different ethnic origins in the European samples (due to language related 
inclusion criteria). This prevented us to control for immunosuppressive regimen and 
ethnic origin. Since the literature suggests that non-adherence is higher in non-white 
kidney transplant patients 1 21 30 50, this may have led to an underrepresentation of 
persons with a low income and socio-economic status in our sample, factors known to 
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be associated with non-adherence behavior 11. It would, with regard to enhancing 
sample representativeness, be worthwile to include more individuals of foreign origin in 
future European studies. 
5.6. Conclusion 
To our knowledge, our study is the first demonstrating a higher probability of US renal 
transplant recipients to be non-adherent compared to European patients, suggesting 
macro level dynamics influencing non-adherence. The differences point to the potential 
importance of health care systems or other system factors in explaining non-adherence 
behavior. Hypothesized pathways through which the health care system might 
influence adherence are at the policy level (macro level) as well as at the 
organizational level (meso and micro level). Future research is needed investigating 
these pathways that might explain differences in non-adherence with 
immunosuppressive medication. 
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6. GRAND DISCUSSION 
6.1. Main considerations 
Adherence to medication regimens is increasingly recognized as a requirement for 
optimal treatment outcomes. Particularly in people with chronic diseases, where life-
long commitment to a prescribed medication therapy is a precondition for a successful 
treatment result, non-adherence can have detrimental health effects 2. Living with a 
kidney transplant is a chronic condition that requires an almost perfect adherence to 
the immunosuppressive therapy to prevent graft deterioration. Despite the dangers 
related to less than perfect adherence, many kidney recipients show non-adherence 
and are thus at risk for rejection episodes or graft loss 3 4. 
The program of research described in this dissertation aimed primarily to investigate 
risk factors of non-adherence to immunosuppressive medication. In our main study, we 
screened a large number of non-adherence risk factors derived from literature, and 
used electronic monitoring (EM), the most sensitive method available to date, to assess 
medication non-adherence. The sample, the largest ever drawn in transplantation 
research on non-adherence, consisted of kidney transplant patients on stable 
immunosuppressive medication. 
Of all tested risk factors, relatively few were significantly related to non-adherence. 
The ones that were (i.e., gender, weekday, self-reported adherence, self-efficacy, 
experiencing spots, pillbox use), showed relationships of moderate strength. The most 
predictive variable for non-adherence as assessed with EM was self-reported non-
adherence, which can be considered as an assessment of past behavior, generally a 
good predictor of future behavior 5. A number of reasons may explain the failure of our 
study to convincingly corroborate the results of past risk factors studies to a larger 
extent. 
Specific methodological characteristics of our study, which differed in several aspects 
from the typical adherence study in kidney transplantation, may provide a first 
explanation. We found an exceptionally high average adherence, which limited 
variability and therefore statistical power but also compromized the generalizability of 
the results (risk factors for non-adherence may differ in high-adherence compared to 
low-adherence samples). Moreover, unlike most other risk factor studies, adherence 
was assessed electronically and not by self-report, two methods known to result in 
different risk factor profiles when tested on identical samples 6-8. Many of the risk 
factor findings reported hitherto in the literature may not be reproducible in EM 
studies. 
Second, our divergent results may be explained by the following three issues in 
adherence research transplantation: 
1.  Adherence research in transplantation declares statistical artifacts as risk 
factors 
2.  Adherence research in transplantation rarely uses behavioral theory to 
guide research 
3.  Adherence research in transplantation does not take context variables into 
account 
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1. Adherence research in transplantation declares statistical artifacts 
as risk factors 
The way statistical findings are interpreted in a large part of the transplant adherence 
literature is misleading. Research papers in the adherence domain seldom report the 
total number of tested variables, but instead, only significant findings. Because of the 
fact that less tests are mentioned than actually carried out, the reported degrees of 
freedom do not correspond to the actually expended ones, resulting in underestimated 
p-values and subsequently profferring scientific discoveries that are in fact sample-
specific stochastic noise 9. Moreover, replication research, which allows to confirm or 
discard previous findings is not very common in the adherence area 6, and thus will not 
redress the evidence base. It is therefore advisable for future research to clearly state 
the total number of tests performed, and/or to make sure that type I errors do not 
accumulate 10 11. 
2. Adherence research in transplantation rarely uses behavioral theory 
to guide research 
Although formal theoretical frameworks explaining behavior (thus also adherence) are 
available from cognitive psychology, and although these could facilitate understanding 
the driving forces behind adherence, few studies use such theories to guide selection 
of risk factors. Theories frequently used in health care are the Health Belief Model 12, 
the Theory of Planned Behavior 13, and the Social Cognitive Theory 14 15. Recently, 
these three theories were integrated into an Integrative Model of Behavioral Prediction 
16 (Figure 2), which states that intentions and environmental or personal constraints 
are the primary determinants of behavior. Intentions are in turn determined by beliefs 
about social norms, self-efficacy (i.e., beliefs of behavioral control), and attitudes (i.e., 
covert feelings of favorability or unfavorability, e.g. outcome expectancy beliefs, 
weighings of pros and cons). Other variables have no direct path to behavior and are 
called distal variables. 
Fig. 2. The Integrative Model of Behavioral Prediction 16 
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The Integrative Model of Behavioral Prediction could serve as a heuristic tool in the 
search for risk factors of adherence behavior. Based on this model, it can be expected 
that attitudes, norms, self-efficacy, or environmental/personal constraints will be the 
strongest risk factors and that distal variables will show less strong associations to 
behavior. Nevertheless, despite their diluted relationship to adherence, distal variables 
are the predominant focus of current adherence research. Studies that aim to 
determine adherence-specific beliefs and/or test if these beliefs are related to 
adherence are rare 17-19. 
 
 
 
Our study included both beliefs, such as self-efficacy 15 and attitudinal beliefs (i.e., 
illness representations) 20 and distal variables. Self-efficacy was related to non-
adherence. Attitudinal beliefs, on the contrary, were not retained in the final results, 
which implies that either attitudinal beliefs did not matter in explaining adherence, or 
that our measurement instrument did not really capture adherence-critical attitudes 19. 
The latter is certainly a possibility, because in contrast to the more successful Long-
Term Medication Behavior Self-Efficacy Scale, which was developed based on published 
qualitative research 18 and was carefully validated 21, the development of the Siegal 
instrument, which was not based on qualitative research, has never been described in 
detail. It is therefore difficult to evaluate whether the Siegal scale has sufficient content 
validity. Because qualitative research is a proper approach for unraveling complex 
phenomena such as context-dependent adherence behavior 22, it may be used to map 
lived experiences of medication-taking in kidney transplant patients, and, hence to 
determine critical attitudinal obstacles to good adherence, which can form the basis of 
a content valid attitudes scale.  
Not much qualitative research has been done on attitudes about immunosuppressives. 
A study by Russell et al. in kidney transplant patients investigated attitudes using semi-
structured questions (n=16) 17, finding that most of patients’ negative attitudes 
towards immunosuppressives referred to side effects of the drugs. None of the items in 
our attitudes instrument assessed attitudes towards side effects. We assessed patient 
perceptions of symptom occurrence and symptom distress using the Modified 
Transplant Symptom Occurrence and Symptom Distress (MTSOSD) scale to explore the 
relationship between symptom experience related to side effects of 
immunosuppressives and adherence. We found a limited number of associations. 
Although the MTSOSD did not really measure attitudes, the relative lack of detected 
relationships possibly suggests that symptoms were not a major driving factor of 
adherence in our sample. Future research should be conducted, exploring whether the 
findings of Russell et al. are generalizable and focusing on the development of a more 
evidence based attitudes instrument. 
Normative beliefs, another group of behavioral determinants, were not measured in 
our study. The qualitative study by Russell et al. also explored normative beliefs related 
to adherence, reporting that patients did not experience a lot of disapproval regarding 
immunosuppressives intake from their social environment. Although this result 
suggests that norms are of minor importance in explaining adherence, it has to be 
noted that one of the limitations of this study was that it only included adults. The 
effect of norms on adherence might be more relevant in adolescents. Adolescents 
There is nothing as practical as a good theory – Kurt Lewin 1 
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suffering from chronic disease are a risk group for non-adherence 23. Being normal and 
autonomous is important for adolescents, however, medication taking may remind 
them of having a chronic disease (=not being normal), induce avoidance coping and, 
hence, non-adherence 23. Future research could give a decisive answer. 
Self-efficacy was also assessed in our study, and although it appeared as one of the 
most powerful predictors of non-adherence, there is probably still room for 
improvement in view of the explanatory power of this belief. The variability measured 
with the Long-term Medication Behavior Self-Efficacy scale is constrained by an 
apparent ceiling effect (i.e., almost all patients mark the maximum score on every 
item, implying that they had very high confidence in their ability to handle the 
presented taxing situation). The high self-efficacy noted in our study reflects the 
sample’s high adherence, but also the fact that items may not adequately represent 
the right challenges the patients face. An extensive discussion of the possible causes 
and remedies of this ceiling effect may be found in previous work published by our 
group 21.  
Among the distal variables included in our study, some were significantly related to 
non-adherence: gender, weekday, self-reported non-adherence, graft type, busyness 
and pillbox use. According to the Integrative Model of Behavioral Prediction, distal 
variables are associated to adherence through mediation by one of the driving forces of 
adherence, be it beliefs or constraints. Although this study was not designed to explore 
the exact causal paths that link distal variables to adherence, it shed some light on the 
way the significant distal variables could affect adherence. Some correlated with 
adherence through a supposed beliefs influence, others through constraints. 
1. Beliefs. A variable that showed an association to adherence through an assumed 
correlation with self-efficacy and/or attitudinal beliefs is ‘graft type’. Living (related) 
graft recipients often show a lower adherence than recipients of a deceased donor 
graft 19 24 25, which may reflect the fact that these persons have a lower self-efficacy 
and a weaker belief that immunosuppressives are important. 
2. Constraints. Variables that showed an association to adherence through an 
assumed effect on ‘personal skills and abilities’ are ‘pillbox use’ and ‘busyness’, and 
probably also ‘weekday’. The most probable causal path is that ‘pillbox use’ decreases 
and ‘busyness’ increases a person’s appeal on memory, thereby influencing a non-
intentional driver of behavior, namely forgetfulness. The path of ‘weekday’ is less 
obvious, but it might be related to the effect of routine in daily life (e.g. adherence is 
lowest during the weekend, when lives are less structured and, hence, reliance on 
memory is higher). An issue supporting the importance of forgetfulness as major driver 
of non-adherence is that patients in many studies rank forgetfulness as the most 
important reason for non-adherence 26-29. Likewise, 66% of patients self-reporting non-
adherence in our study mentioned forgetfulness as reason. Another issue supporting 
the importance of constraints comes from the fact that self-efficacy showed a more 
convincing relationship to adherence than attitudinal beliefs (if we take for granted that 
the Siegal scale measured the right attitudes). Self-efficacy reflects one’s perceived 
ability to cope with constraints. If constraints are a major driver of non-adherence, it 
can indeed be expected that the confidence to adhere despite constraints (= self-
efficacy) will be positively related to adherence.  
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Thus, our findings suggest that non-intentional factors are a major driver of non-
adherence. Non-intentional factors possibly explain more of adherence behavior than 
intentional beliefs do, which may be a reason for the observed high adherence level in 
our EM study. High adherence could namely reflect the relative absence of intentional 
non-adherence. The results of our study are therefore not automatically relevant for 
populations with a typically lower adherence level (e.g. hypertension patients 21). This 
hypothesis, that non-intentional factors are more important than intentional factors in 
explaining non-adherence in kidney transplantation should be investigated further. 
3. Adherence research in transplantation does not take context 
variables into account 
Context is an important but mainly neglected aspect of the daily reality in which 
adherence behavior takes place. In the Integrative Model of Behavioral Prediction, 
context is mentioned under the distal variable category ‘culture’. Culture is, however, 
only one aspect of context. Context refers to any higher-level variables that exert a 
possible influence down to the individual subject level.  
An example may clarify the concept of ‘context’. In many scientific disciplines it 
became clear that behavior of study subjects cannot be explained well if the 
characteristics of the system of which they are part are neglected. In pedagogical 
research for instance, it has long be acknowledged that explaining achievements of 
pupils requires not only taking into account pupil-related variables such as intelligence, 
motivation, or self-efficacy, but also higher level variables like teaching style, school 
atmosphere, and educational system 30. These variables reflect a system’s emergent 
properties not reducible to individual-level characteristics. Including these emergent 
variables in a statistical model contributes to its explanatory power. 
Health care system variables like financial burden of immunosuppressive intake for the 
patient, level of chronic illness management in a setting, trust in health care workers, 
or communication style of health care providers might impact patient behavior in much 
the same way as teaching style or school system do in pupils 31. Like school 
performance, adherence behavior is bound to and fundamentally influenced by the 
social environment in which it is stimulated (or not stimulated). Patients in one 
environment may have different contextual experiences from patients “nested” in other 
environments, a reality requiring design and analysis adaptations that only recently 
have entered the mainstream 32 33. Congruent with research in sociology, pedagogy, 
and economy, it is time that health research abandons the idea that patient behavior 
originates in a social vacuum. Statistical practice should reflect this nested social reality 
by involving higher level variables and use the currently available analytical techniques 
to fit such models. 
By performing the meta-analysis reported in chapter four, our research group is among 
the first to carefully examine non-adherence risk factors at both the level of individual 
patients and the systems in which they receive their care 34. This meta-analysis needs 
to be regarded as a pilot project to explore the feasibility of undertaking a multi-level 
study on possible differences in adherence in kidney transplant patients treated in 
different health care systems. We are planning a multi-center study in the near future 
to investigate the impact of different macro- and meso-level characteristics of health 
care on patient adherence. This study, which will draw a clustered convenience sample 
of heart transplant centers in the US and Europe and will be performed in collaboration 
with the Center for Health Services and Nursing Research at the Catholic University of 
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Leuven and with the International Transplant Nursing Society, will include meso-level 
variables like composition and skill mix of the multidisciplinary team and level of 
implementation of chronic illness management, communication style of the health care 
worker, trust in the treating physician, next to macro-level data such as hospital 
system, type of health insurance, or organization of the pharmacy system. 
6.2. Intervention research 
A better understanding of adherence, which may result from addressing the three main 
shortcomings of adherence research in transplantation (statistical, theoretical, and 
multi-level) should contribute to the development of more targeted adherence-
enhancing interventions and the improvement of transplant outcomes.  
Adherence intervention research is limited in transplantation. Some adherence-
enhancing intervention strategies have been described 35-38. Only two studies formally 
tested interventions to improve adherence to immunosuppressives in the transplant 
population 39 40, These interventions, as well as systematic reviews summarizing 
intervention studies in  other chronic-, and acute-care populations (meta-analyses 41 42; 
narrative reviews 43-45) might be used to develop future interventions. Improved 
adherence is a difficult goal to attain, especially for long-term medication treatments. 
The best results are achieved by complex approaches combining educational, cognitive 
behavioral, and social support interventions at multiple levels (e.g. interventions 
towards health care professionals or realizing changes in the health care system) over 
a sustained time that target more than one risk factor 43 46. Studies based on strong 
theory or conceptual frameworks likely will contribute to more effective adherence 
interventions. Few interventions are theory based. Our study used the self-efficacy 
concept as a conceptual basis. Using theoretical models such as the self-efficacy theory 
or the Integrative Model will, however, probably not be sufficient to induce behavioral 
change. Extending the explanatory theoretical models with evidence from behavioral 
change research is therefore advisable. Behavioral change models, such as the Stages 
of Change model 47, provide greater detail of how to get people to change their beliefs 
and eventually, their behavior. Attempts to combine the Integrative Model and the 
Stages of Change model have already been undertaken 48. Such integrations could be 
useful for designing future intervention programs. 
6.3. Electronic medication monitoring 
In addition to the main goal of this dissertation, i.e. mapping risk factors of non-
adherence, we also focused on a methodological issue, namely the measurement of 
non-adherence. We developed a framework for validating EM, contribution to 
adherence research as no systematic attempt to validate the EM system has been 
carried out in its two decades of existence. We demonstrated the existence of an 
intervention effect of EM, after almost 20 years of related debate in the literature. 
Recent statistical techniques allowed us to map time- dependent medication dynamics 
in a multivariable way (i.e., generalized linear and generalized additive models). As 
outlined in appendix 1, there remains room for improvement in using the generalized 
linear model technique for longitudinal studies. A recent replication test of this 
intervention effect by our group in HIV patients confirmed our findings in transplant 
patients, thereby supporting the external validity of the results presented in this 
dissertation 49. 
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Aside from the intervention effect, we also found that failing technology and 
mismatches between pill intakes and bottle openings may bias EM measurement. 
Mismatches have the farthest reaching implications for setting up future EM studies. Its 
bias can be largely prevented by offering patients an option to register mismatches 
between pill intakes and an by assessing their adherence to the EM guidelines. Patients 
showing major non-adherence to the EM guidelines should be excluded to prevent that 
missing data from not using EM are considered to reflect non-adherence. To what 
extent these excluded patients differ from those not excluded remains to be examined. 
6.4. Final summary 
Summarized, we conclude that research on risk factors of non-adherence in kidney 
transplantation can still be improved, both content-wise and methodologically. 
Research should be more guided by behavioral theory, and should consider effects of 
the social system in which patients are cared for. Our research group will take the lead 
in investigating this latter research area by setting up an international multi-center 
study with the goal to explore higher-level system correlates of (non-) adherence. Our 
hope is that this will lead to an enhanced understanding of adherence behavior, so that 
health care professionals get a better grip on non-adherence and its detrimental 
consequences. 
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7. APPENDIX 1: VALIDATION OF THE RANDOM-EFFECTS 
MODEL 
Despite having advantages over previously proposed methods to analyse EM data in a 
longitudinal way 1 2, generalized Linear Mixed Models (e.g., random-intercepts logistic 
regression analysis) have their own drawbacks. Results are unbiased if certain 
assumptions are not violated. Overdispersion and serial dependency are two processes 
that may violate these assumptions.  
7.1. Overdispersion 
Logistic regression assumes binomial errors, with estimated variance (y) = m(1 - m), 
where m is the estimated mean residual. "Overdispersion" occurs when the observed 
variance of the residuals is greater than the expected variance, and indicates 
misspecification of the model, non-random sampling, or an unexpected distribution of 
the variables. As a result, standard errors will be over-optimistic, leading to confidence 
intervals that are too wide. Examination of overdispersion can be done using the GLMM 
procedure from the ‘lme4’ package that runs on the statistical R-platform 3. The 
program GLMM procedures fits a Generalized Linear Mixed Model by estimating the 
maximal likelihood with Laplacian approximation to the marginal likelihood instead of 
by using numerical quadrature as the NLMIXED procedure in SAS does. Fitting a model 
as the one presented in table 3 on page 50, showed that the estimated dispersion 
parameter approached the theoretically expected value of 1, suggesting that the model 
fit the data well. 
7.2. Serial dependency 
One drawback of Generalized Linear Mixed Model procedures is that they assume 
independence of observations within one patient, an assumption that might be violated 
in longitudinal studies, because observations closer in time generally resemble more 
than observations further away 4. To detect whether such a serial dependency 
occurred in our study, we performed a runs test on each patient’s binary adherence 
sequence. Runs tests allow to control if a binary sequence is random. 
A runs test could be performed in 182 patients of the 249 patients with EM data. After 
controlling for multiple testing 5, 11 sequences differed significantly from random 
(q<0.05), suggesting serial dependency. The size of the runs test’s p-value highly 
correlated with the taking adherence parameter (Spearman’s rho=0.60), suggesting 
that serial dependency became worse when patients were more adherent. Redoing the 
main analysis of the EM-validation study while omitting all patients that had a runs test 
p-value <0.05 did not change the results as presented in table 3 on page 50, nor in 
terms of estimates, nor in terms of inferences. This result indicates reality is more 
complex than today’s available modelling techniques can capture, but that the 
existence of serial dependency did not lead to bias.  
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8. EXECUTIVE SUMMARY 
8.1. Background and aim of the research program 
Non-adherence to the immunosuppressive therapy is an important issue in kidney 
transplant patients. About 20% of the kidney transplant patients are non-adherent to 
the immunosuppressive regimen. Non-adherence contributes to 20% of late acute 
rejection episodes and 16% of the graft losses, and results in a decreased number of 
quality adjusted life years. A strategy to increase long-term successful outcome after 
transplantation is to identify patients at risk for non-adherence and to target them for 
preventive and adherence enhancing interventions. Comprehensive research on risk 
factors of non-adherence addressing socio-economic, patient-, condition-, therapy-, 
and health care system/worker-related factors is lacking. Especially health care-related 
risk factors are understudied. Moreover, existing studies are hampered by a number of 
methodological shortcomings. An important shortcoming is that accurate measurement 
methods for detecting non-adherence, such as electronic monitoring (EM) are rarely 
adopted. EM, currently the most sensitive adherence assessment method, uses 
microchip technology to register date and time of openings of a pill bottle. Although 
EM’s superior sensitivity to detect non-adherence makes it a potential gold standard of 
adherence assessment, the lack of thorough validation as well as the lack of use of 
appropriate statistical methods for multivariable and/or longitudinal data analysis of EM 
data, hinder progress in the field.  
The main purpose of this research program was to determine prevalence and risk 
factors of non-adherence to immunosuppressive medication in kidney transplant 
patients. As an additional purpose, we aimed to improve the validity of EM 
measurement by mapping assumptions underlying correct EM measurement. We 
tested these assumptions on adherence data of kidney transplant patients. 
8.2. Methods 
8.2.1. Prevalence and risk factors of non-adherence 
To study prevalence and risk factors of non-adherence to immunosuppressives, we 
conducted a prospective study, in which we measured adherence by EM over a 3-
month period in 250 adult renal transplant patients sampled from two outpatient 
transplant centers in Switzerland. We calculated period prevalences of adherence and 
expressed them as the percentage of prescribed doses taken (taking adherence), the 
percentage of days with correct dosing (dosing adherence), the percentage of inter-
dose intervals not exceeding 25% of the prescribed interval (timing adherence), and 
the number of drug holidays per 100 days (>48h no intake if once; >24h if twice daily 
intake).  
Selected risk factors were socio-economic, therapy related (e.g. number of 
transplantations, use of medication aids, symptom occurrence and distress), patient 
related (e.g. self-efficacy, health beliefs, coping styles, busyness, health behaviors), 
condition related (e.g. depression, substance use), and health care system/team 
related (e.g. regularity of follow up). Testing of the risk factors occurred by simple 
mixed logistic regression analysis, using a sequence of daily binary adherence data. 
Factors significant after correction for multiple testing were entered into a multiple 
mixed logistic regression model.  
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Because the EM-study was not designed to extensively investigate health care system 
or health care team-related factors, we performed an additional meta-analysis to look 
whether non-adherence prevalences differed between continents/countries. This meta-
analysis on individual patient data pooled data from three studies in adult kidney 
transplant patients from the US (n=1563), the Netherlands (n=85), Belgium (n=187) 
and Switzerland (n=342). Adherence was measured by the Siegal scale, a self-report 
instrument for measuring non-adherence to immunosuppressives. Patients were 
categorized as non-adherent if they reported to have missed a dose of 
immunosuppression in the last 4 weeks. Data were analysed using multiple mixed 
logistic regression with center as a random effect and continent/country as fixed 
effects, while controlling for several demographical and clinical characteristics of the 
included samples. 
8.2.2. Validation of EM assessment 
To study the validity of the EM measurement, we summarized existing evidence on 
processes that may bias non-adherence assessment. Unbiased EM assessment requires 
fulfillment of four validity assumptions, being (1) correctly functioning EM equipment, 
(2) correspondence of EM-bottle openings to the actual intake of the prescribed dose, 
(3) absence of influence of EM on a patient’s normal adherence behavior, and (4) 
sample representativeness.  
We examined these four validity assumptions using the above mentioned sample of 
250 kidney transplant patients whose adherence was measured by EM. More 
specifically, we (1) determined the prevalence of non-functioning EM systems, (2) 
examined the impact of patient-reported discrepancies between cap openings and 
actual drug intakes on period prevalence, (3) explored whether non-adherence 
increased over time after patients started EM, and (4) screened for differences 
between participating patients and patients who refused to participate or who dropped 
out of the study.  
8.3. Results 
Mean taking, dosing, timing adherence and drug holidays per 100 days were 98%, 
96%, 93%, and 1.1 days, respectively. Variables associated with EM measured non-
adherence were: higher self-reported non-adherence (OR= 3.08; 95%CI: 1.69-5.61), 
no usage of a pillbox (OR= 0.31; 95%CI: 0.16-0.61), male gender (OR= 0.46; 95%CI: 
0.26-0.81), and lower self-efficacy (OR= 0.49; 95%CI: 0.22-1.07). Furthermore, a 
gradually declining adherence could be observed between Monday and Sunday (OR= 
1.04; 95%CI: 1.02-1.07).  
The results of the meta-analysis examining self-reported non-adherence differences 
between continents/countries showed that the prevalence of non-adherence to 
immunosuppressives in the U.S. and Europe was 19.3% and 13.2.%, respectively The 
higher prevalence of non-adherence in US patients was confirmed in the multiple 
logistic regression analysis (OR=1.78; 95%CI: 1.10-2.89). Moreover, non-adherence 
differed between Belgium (16%) and the Netherlands (14.1%) (OR=0.27; 95% CI: 
0.09-0.80) and between Belgium and Switzerland (11.4%) (OR=0.17; 95% CI: 0.0-
0.42). 
The validation study of EM showed that not all assumptions underlying EM 
measurement were fulfilled: (1) one cap malfunctioned, (2) mismatches between bottle 
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openings and actual drug intake occurred in 62% of the patients (n=155), and (3) 
non-adherence increased during the initial period of the monitoring, primarily during 
the first 5 weeks, indicating EM had an intervention effect. The bias caused by this 5-
week intervention effect was minimal. The effect of mismatches between bottle 
openings and actual drug intake on the measured adherence prevalence was larger, 
but could be minimized by correcting the downloaded EM data using patient self-
reports (i.e., self-reported adherence to the EM guidelines and notes made by the 
patient to correct mismatches between openings and ingestions). 
8.4. Conclusions 
This study program aimed to study risk factors of non-adherence in kidney transplant 
patients. Its contribution to the literature lies in the fact that a comprehensive number 
of non-adherence risk factors, including the currently neglected health care system 
factors, have been explored, and in the fact that improvements of the methodological 
approach for adherence studies have been proposed. 
The profile of risk factor appearing in the final results suggest that forgetfulness was a 
major driver of non-adherence. Moreover, system factors might also have an impact on 
individual adherence behavior, as suggested by the found differences in prevalence of 
non-adherence between European and US patients and among European patients. 
These findings may change the focus of adherence research in the transplant 
population. 
Methodological improvements put forward throughout this study program primarily 
concern the measurement of adherence behavior using EM. Novel statistical techniques 
are proposed that allow multivariate analysis of EM data and inclusion of time-varying 
variables into the statistical regression models. Besides, we showed that, although 
assumptions underlying valid EM measurement may be violated, bias can to a certain 
extent be prevented by correcting incorrect data or omitting them from the analysis. 
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